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Summary
The M94 gene of murine cytomegalovirus (MCMV) is one of the about 40 core genes of
the subfamily of β-Herpesvirinae with unknown function. MCMV is utilised as an in vivo
model for studying human cytomegalovirus (HCMV) due to the strict species specifity
of HCMV and major homologies to MCMV. HCMV is an important human pathogen
with worldwide distribution. Although infection of the immune competent host is usually
clinically silent, infection of the foetus and the newborn causes severe organ damage and
infection of immunocompromised patients induces life-threatening disease.
M94 has not been studied intensely as a single gene before, but studies on its homologues
in other Herpesviridae demonstrated expression as true late gene, presence in the virion,
interaction of UL94 and UL99 in HCMV and capsid binding in α-Herpesvirinae. While
UL94 in HCMV is essential, M94 homologues in α-Herpesvirinae are not essential, indicat-
ing an essential function of M94 conserved in β-Herpesvirinae but lost in α-Herpesvirinae.
For the identifaction of this essential function, a library of random mutants was generated
by a modified Tn7 transposon mutagenesis. The modifications in the transposon mutagen-
esis produced a library of high diversity and wide coverage containing 32,000 primary clones
including stop and insertion mutants. The analysis of 613 clones by sequencing resulted in
399 unique mutants containing a correct 15 base pair (bp) insertion in M94. 116 stop and
insertion mutants were individually reinserted into the viral genome and studied in the
viral context. The primary analysis showed the ability of certain mutants to complement
the M94 deletion, thereby identifying the essential regions in the M94 protein. Secondly,
the M94 mutants were re-inserted as second gene and analysed for their inhibitory capacity
Summary xvi
of the M94 wild type (wt) functions to identify dominant negative (DN) mutants. The
inhibitory mutants found were then verified as DN mutants by regulated expression in the
virus context and by analysis of their specific phenotype induced by overexpression.
Further analysis of the DN mutant in comparison to a M94 deletion mutant revealed no ef-
fect of M94 in viral cleavage-packaging, despite previous publications. Additional analysis
showed a block in secondary envelopment for both the DN mutant and the deletion mutant
and the determination of the spread deficient phenotype of the M94 deletion virus. Alto-
gether these results constitute a new model for secondary envelopment in β-Herpesvirinae.
Zusammenfassung
Das M94 Gen des murinen Cytomegalovirus (MCMV) ist eines der ungefa¨hr 40 Kerngene
aus der Unterfamilie der β-Herpesvirinae mit unbekannter Funktion. MCMV dient als
in vivo Modell zum Studium des humanen Cytomegalovirus (HCMV), da HCMV eine
strikte Spezies-Spezifita¨t aufweist und große Homologien zu MCMV bestehen. HCMV
ist ein wichtiges humanes Pathogen mit weltweiter Verbreitung. Obwohl die Infektion im-
munkompetenter Wirte normalerweise klinisch unauffa¨llig verla¨uft, verursacht die Infektion
von Fo¨ten und Neugeborenen schwere Organscha¨den und die Infektion immunsupprimierter
Patienten ruft lebensbedrohliche Krankheiten hervor.
M94 als Einzelgen wurde zuvor nicht intensiv studiert, aber Studien u¨ber seine Homologe
zeigten seine spa¨te Expressionskinetik und seine Existenz als Teil des Virions. Es wurde
eine Interaktion von UL94 mit UL99 in HCMV entdeckt und in α-Herpesvirinae eine
Bindung der M94 Homologen an Capside. Wa¨hrend UL94 in HCMV essentiell ist, sind
M94 Homologe in α-Herpesvirinae nicht essentiell. Dies la¨sst auf eine essentielle Funktion
von M94 schliessen, die in β-Herpesvirinae konserviert ist, aber nicht in α-Herpesvirinae.
Zur Identifikation dieser essentiellen Funktion wurde durch eine modifizierte Tn7 Transposon-
Mutagenese eine Bibliothek von zufa¨lligen Mutanten erstellt. Durch die Modifikationen
in der Transposon-Mutagenese wurde eine Bibliothek erzielt, welche hohe Diversita¨t und
große Abdeckung mit 32.000 prima¨re Klone mit Stopp- und Insertionsmutanten aufwies.
Die Analyse von 613 Klonen durch Sequenzierung resultierte in 399 individuellen Mutanten
mit einer korrekten 15 Basenpaar Insertion in M94. 116 Stopp- und Insertionsmutanten
wurden einzeln in das virale Genom inseriert und im viralen Kontext gepru¨ft. Die prima¨re
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Analyse offenbarte die Fa¨higkeit der Mutanten die M94 Deletion zu komplettieren, dabei
wurden die essentiellen Regionen im M94 Protein identifiziert. Zweitens wurden die Mu-
tanten auf ihre inhibitorische Kapazita¨t in Anwesenheit des M94 Wildtyp Allels analysiert,
um dominant negative (DN) Mutanten zu identifizieren. Die identifizierten inhibitorischen
Mutanten wurden als DN Mutanten durch regulierte Expression im Viruskontext und Anal-
yse ihres spezifischen Pha¨notyps whrend der U¨berexpression verifiziert.
Die weitere Analyse der DN Mutante im Vergleich zu einer M94 Deletionsmutante offen-
barte keinen Effekt auf virales Cleavage-Packaging, trotz fru¨herer Publikationen. Zusa¨tzliche
Analysen zeigten eine Blockierung der zweiten Umhu¨llung sowohl fu¨r die DN Mutante als
auch fu¨r die Deletionsmutante und den ausbreitungsdefiziente Pha¨notyps des M94 Dele-
tionsvirus. Zusammen zeigen diese Resultate eine wichtige Funktion von M94 bei der
zweiten Umhu¨llungsphase der β-Herpesvirinae auf.
Chapter 1
Introduction
1.1 Herpesviridae
Herpesviruses are large double stranded DNA viruses causing latent and lytic infections in
animals including humans. The order of the Herpesvirales consists of three families, the
Alloherpesviridae including herpesviruses of fish and amphibians, the Malacoherpesviridae
containing herpesviruses of the bivalves and the Herpesviridae with herpesviruses of mam-
mals, birds and reptiles [51]. The latter virus family developed from a common ancestor
around 400 million years ago [50] and sepatated into three subfamilies, the α-Herpesvirinae,
the β-Herpesvirinae and the γ-Herpesvirinae. This classification was based on biological
properties in the 1970s and is proved by sequence analysis of Herpesviridae genomes to-
day [76].
The α-Herpesvirinae are characterised by a wide host range, a short replication cycle, fast
dissemination in cell culture, viral host shut-off, efficient lysis of infected cells and estab-
lishment of latency predominantly in neurons. In contrast, β-Herpesvirinae have a more
restricted host range and a longer replication cycle. They spread slower in cell culture
with milder cytopathic effects and latency can be established in different cell types. Simi-
lar to the β-Herpesvirinae the γ-Herpesvirinae exhibit a restricted host range and replicate
slowly if at all in cell culture. In contrast to the α-Herpesvirinae, which can lytically in-
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fect almost all cell types, the γ-Herpesvirinae are lymphotropic and also establish latency
in lymphoblasts [66]. The well known Epstein-Barr virus (EBV), which causes infectious
mononucleosis, also known as kissing disease, is a member of the γ-Herpesvirinae. The
most prominent members of the α-Herpesvirinae are the herpes simplex virus (HSV) and
Varicella-zoster virus (VZV), whereas the β-Herpesvirinae are represented by HCMV and
MCMV.
Traditionally the lytic infection cycle of Herpesviridae is investigated in α-Herpesvirinae
due to their short replication cycle. Additionally, HSV was the first isolated herpesvirus
[34]. In the majority of cases, new details on the lytic cycle are detected in α-Herpesvirinae
and subsequent confirmed in β-Herpesvirinae, whereas immunological studies are per-
formed mainly in β-Herpesvirinae due to established MCMV model in mice for HCMV.
The research in γ-Herpesvirinae examines transformation of cells, unique among the Her-
pesviridae.
The protein M94 investigated in this study is involved in the lytic cycle of MCMV. This
study represents a case of a functional analysis of a herpes viral protein involved in the
lytic cycle primarily in β-Herpesvirinae.
1.1.1 Clinical relevance of human cytomegalovirus
Human cytomegalovirus shows a worldwide distribution within humans as its exclusive
host. Depending on the socio-economic status 50-100 % of the adult population is seroposi-
tive, where lower socio economic status correlates with higher infection rate [11,62]. HCMV
infection in the immune competent host is usually clinically silent. Spread of HCMV occurs
via horizontal transmission as well as vertical transmission.
The most common transmission route is vertically from mother to child either prenatal,
perinatal or via breast feeding. Prenatal infection through the placenta and perinatal in-
fection by virus shedding during birth in the maternal genital tract [74] can cause organ
threatening disease. Although the most common route for vertical transmission is breast
feeding [26], infection usually proceeds clinically silent and congenital infection is the clin-
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ically most relevant form. Infection of the foetus can occur as a result of recurrence from
latency as well as from primary infection of the mother [87] and leads to severe damage
of the foetal organs or central nervous system [78]. Congenital HCMV infection therefore
has been estimated to be the leading cause for sensorineural deafness and brain damage in
children [65].
Horizontal transmission requires direct contact of a susceptible person with infectious body
fluid such a urine, saliva, tears, semen, and cervical secretions, where it can be detected
for month to years after initial infection [59]. Therefore, horizontal transmission of HCMV
correlates with contact to young children and sexual activity [2, 12]. Horizontal transmis-
sion also occurs through blood transfusion [1] or solid organ [37, 75] and bone marrow
transplantation [32].
Additionally, HCMV is one of the most common and difficult opportunistic pathogens that
complicates the care of immunocompromised patients, such as AIDS and transplant pa-
tients [29,86], inducing esophagitis, gastroenteritis, retinitis, pneumonia and mononucleosis
like illness [16,44]. At the moment there is no vaccine available. Thus, a potential HCMV
vaccine was identified as one of the most cost effective and efficient ways to enhance life
quality [90].
1.1.2 The murine cytomegalovirus model of HCMV
As a result of its strict species specificity, studies on HCMV in vivo are restricted by the
guidelines on experiments involving humans. Therefore, as they show a high homology in
genome sequence [70] and similar infection biology [39], MCMV was established as a model
for CMV infection in vivo. With this reactivation from latency as well as viral immune
evasion strategies can be studied in detail as well as dissemination of virions in the organism
and establishment of latency. Although resulting findings cannot be directly transferred
to HCMV, there are established mouse models to mimic certain clinical situations such as
bone marrow transplantation [67] and human leukocyte antigen transgenic mouse models
proved to be useful for HCMV epitope identification and preclinical vaccination studies [69].
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Figure 1.1: Schematic representation of the
HCMV virion (adapted from [73]). The major
virion components are indicated.
1.1.3 Structure of cytomegaloviruses
The composition of cytomegalovirus infectious particles is similar to other herpesviruses
(Fig. 1.1). The mature virion has a diameter of 200-300 nm containing the viral capsid
surrounded by tegument [31], an amorphous, proteinaceous layer [14] that is sequentially
acquired during virus maturation [56]. The envelope is derived from the Golgi/trans-
Golgi compartment and contains several virus encoded glycoproteins [28]. The icosahedral
capsid has a diameter of 130 nm and contains the viral DNA. As every herpesvirus capsid,
it is composed of 162 capsomers out of 150 hexons and 12 pentons. The five proteins
constituting the hexons and pentons are conserved among the Herpesviridae [8]. The
capsid protects the viral DNA against external influences. The viral genome in discussed
in more detail in the next section.
1.1.4 The genome of cytomegaloviruses
The genomes of HCMV and MCMV consist of approximately 230 kbp of double stranded
(ds) DNA and are together with the pox viruses the largest among vertebrate viruses. The
genome of MCMV is a single unique sequence with short direct repeats at either end [27],
whereas the genome of HCMV is separated by internal repeats into a unique long and a
unique short region [13]. Additionally, the genome is flanked by terminal repeats, including
multiple copies of a-sequences. These contain several repeats and two unique sequences
which generate the pac1 and the pac2 signal, which determine the sites for viral DNA
cleavage and packaging [17].
The Herpesviridae share common genome architecture. The conserved genes are located in
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the middle of the genome, flanked by subfamily specific genes and surrounded by species
specific genes at both ends of the genome (Fig. 1.2). The core genes are arranged in 7 gene
blocks. In one cluster the gene order and polarity are conserved, whereas the order of the
gene blocks varies between the subfamilies (Fig. 1.2).
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Figure 1.2: Schematic diagram of herpesvirus genome organisation for all 3 subfamilies (modified from [59]). The herpesvirus
genomes consist of species specific genes located at both end, with subfamily specific genes within. The inner part is composed
of the core genes with the 7 conserved gene blocks. These are enlarged for every subfamily in the next lines. The gene order
and orientation is conserved within the subfamily, whereas the order of conserved gene blocks varies between the subfamilies.
1.1.5 Replication of cytomegaloviruses
As discussed previously the models for lytic infection are predominantly based on HSV and
are devolved on CMV. An overview of the herpesvirus life cycle is illustrated in Fig. 1.3.
The virus enters the cell by binding to specific cell surface receptors and fusion of the viral
envelope with the cellular membrane. For example, heparan sulphate proteoglycans are
among the receptors for HCMV [20]. The capsid is then delivered into the cytoplasm and
transported to the nucleus via microtubuli where the viral DNA is released [84]. After
circularisation of the DNA in the nucleus, gene expression is initiated.
Gene expression in the lytic cycle is strictly regulated and executed in a cascade man-
ner [38], starting with expression of immediate early (IE) genes. The IE proteins induce
the transcription of most other viral genes and also affect the host cell [94]. Thereby, innate
immune response and apoptosis are inhibited and the cell is prepared for viral replication.
The genes expressed upon IE induction are called early genes and their expression proceeds
6 to 24 h post infection (pi) [94]. Most of these gene products are involved in viral DNA
replication and also in modulation of host immune response.
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The replication of viral DNA, which starts 14-16 hpi leads to the expression of late genes.
It is still unclear whether the expression of late proteins starts with the viral DNA replica-
tion or increases to detectable limits by this stage of infection. These proteins are involved
in capsid maturation as well as DNA encapsidation and egress, processes that lead to pro-
duction of infectious viral particles. Only a few genes are dependent on DNA replication
for their expression, these are called true late genes.
The viral genome replication produces head-to-tail concatemers, which are cleaved into
unit length genomes simultaneously to insertion into the capsid [52]. The capsid assembly
itself also takes place in the nucleus. It is composed of 5 conserved proteins, arranged into a
procapsid, which matures to the final capsid by protease cleavage and DNA insertion [55].
The capsid leaves the nucleus by budding into the perinuclear space, so called primary
envelopment, and is transported from there by fusion of the primary envelope with the
outer nuclear membrane into the cytoplasm [30]. On the way to the plasma membrane
via the secretory pathway the tegument is added and the final or secondary envelopment
occurs at the trans Golgi network (TGN) [79]. The mature virion is then transported to
the cell surface and secreted into the extracellular space.
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Figure 1.3: Diagram of the herpesvirus life cycle (adapted from [19]). The virion enters the cell by fusion with the plasma
membrane after attachment via glycoproteins. This leads to release of the viral capsid into the cytoplasm. The capsid is
then transported to the nucleus, where the viral genome is inserted into the nucleus through nuclear pore and circularises.
Transcription is separated into 3 phases. Starting with the transcription of immediate early genes (orange), which activates
the transcription of early genes (green). The translated early genes induce the replication of the viral genome and also
the expression of the late genes (blue). These are mainly structural proteins and provide the components for virus capsid
assembly. The viral DNA is then encapsidated into preformed capsids. These leave the nucleus by budding in an enveloping-
and de-enveloping event and traverse the cytoplasm to the trans-Golgi-network while virion maturation proceeds. The mature
virion is finally exocytosed into the extracellular space.
1.2 Genetics of herpesviruses 8
1.2 Genetics of herpesviruses
Since analysis by molecular cloning, the mutation of genes served as a powerful tool to
analyse their function. Accordingly a mutagenesis was utilised for functional analysis in
this study, the basic mutagenesis strategies will be explained. Mutagenesis of a defined
gene and investigation of the resulting phenotype (reverse genetics) is thus distinguished
from investigation of the genetic background of a known phenotype (forward genetics).
1.2.1 Forward Genetics
Early mutagenesis strategies were dependent on chemical agents or UV radiation for en-
hancement of the mutation rate during replication [40]. Interesting phenotypes were then
investigated for their genetic background. Originally, temperature sensitive mutants were
preferred as these mutants replicate like wt at permissive temperature and demonstrate
the mutant phenotype only at the non-permissive temperature, facilitating the production
of mutant virus and investigation of its phenotype [80].
The mutation causing the phenotype was identified using cross-complementation and marker
rescue. Therefore a genome sector next to a marker was inserted into infected eukaryotic
cells. Recombination events due to homologies with the viral genome were selected by the
marker. The absence or presence of the mutant phenotype in the recombined viruses led
to localisation of the mutation. This procedure was time-consuming and work-intensive.
1.2.2 Reverse Genetics
After identification of the mutation in the forward genetics, it remained unclear whether the
phenotype arose from a single or multiple mutations. The discovery of molecular cloning
and the publication of the MCMV genome opened the route for specific mutageneses of viral
genes by homologous recombination [58]. Viral genes could be mutated and propagated
in Escherichia coli (E. coli) and inserted into infected eukaryotic cells (Fig. 1.4). By
homologous recombination at flanking homologies the viral gene could be substituted by
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the mutated gene and a selectable marker in infected cells [85]. Due to the selectable
marker the mutated genome could be separated from wt genomes. The mutation was
established by this procedure and the resulting phenotypes could be analysed.
1.2.3 Mutagenesis of bacterial artificial chromosomes
The homologous recombination in eukaryotic cells produced low amounts of mutant virus
which needed to be purified from wt virus. By cloning the MCMV genome as bacterial
artificial chromosome (BAC) [54] the mutagenesis and genome propagation was carried out
in E. coli. The resulting genome was pure from wt contamination and only the mutated
virus was reconstituted from the mutant BAC (Fig. 1.4). The homologous recombination
occurs in E. coli by ET recombination [97] and this was adapted by our lab for the CMV
mutagenesis using linear DNA fragments [92]. Subsequently cells are transfected with the
mutant BAC and the mutant virus was reconstituted. Hence, every conceivable mutation
can be introduced into the virus.
1.2.4 Random mutagenesis
Stuctural knowledge of a protein permits the application of reverse genetics as specific
sequences can be targeted by a selected mutation. Without structural information of the
protein a random mutagenesis procedure is required. There are several techniques for
random mutageneses established such as application of a mutator E. coli strain [33] or
error-prone polymerase chain reaction (PCR) [42]. For this study the transposon mutage-
nesis was chosen, as it almost guarantees a single mutation in the gene of interest and next
to insertion mutants stop mutants are also generated.
Transposons are mobile genetic elements which can insert into DNA sequences. The cor-
responding reaction is named transposition and different mechanisms are known. The
relevant one in this study is the class II transposon. In this reaction a transposon is
excised or copied from a donor position by the respective enzyme, the transposase, and
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Figure 1.4: Strategies for mutagenesis in reverse genetics. Mutagenesis of a gene in E. coli and subsequent homologous
recombination in eukaryotic cell with the viral genome, resulting in mutated and wt viral particles, is depicted in A, whereas
B illustrates the mutagenesis of BAC in E. coli and reconstitution of the mutant BAC in eukaryotic cells.
inserted into a non-homologous target site. The first transposon was discovered in 1948 in
maize [49], but the transposon Tn7 utilised in this study originates from bacteria [5] and
permits a random insertion of the transposon into the target vector [6].
Mutagenesis of the BAC by transposon insertion is comparable to chemically induced
mutagenesis, but only a single mutation is introduced by the transposon. Consequently
essential and non-essential viral genes can easily be identified as essential genes destroyed
by insertional mutagenesis prevent viral reconstitution from the BAC [9]. For the mutage-
nesis of a single viral gene, the gene is subcloned into a vector and the mutagenesis occurs
on the plasmid. Mutants are subsequently inserted into the BAC deleted in that gene.
The reconstitution of virus reveals the influence of the mutation on the protein function.
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This method was utilised in this study.
1.2.5 Dominant negative mutants
The term antimorphic mutation, which was later renamed as dominant negative mutation,
was introduced by Hermann Joseph Muller on the Sixth International Congress of Genetics
in 1932 [60]. A DN mutation is defined as mutation leading to mutant protein that disrupts
the activity of the wild type gene when overexpressed [36]. Therefore a DN protein must
fulfil at least two functions. One function will remain intact as in the parental wild type
protein, but another function is disrupted either by deletion of this protein domain or by
its mutation to non-functionality.
For example, the DNA-binding domain of a transcription factor remains intact, but the
activation domain is mutated. The DN mutant protein thereby blocks the wt protein from
binding to the DNA by occupying the binding site itself, but does not continue in gene
activation, thereby inhibiting wt function. Another example would be a DN mutant in a
multimeric complex. The mutant would allow complex formation but not the execution
of its downstream functions. Hence, DN mutants affect interactions either of proteins and
DNA or among proteins.
An expressed DN mutant can result in the same phenotype as a deletion mutant. However
the investigation of a deletion mutant demands a trans-complementing cell line. This
obstacle can be avoided by the conditional expression of a DN mutant. Thereby the mutant
virus can be produced regularly and the mutant phenotype is induced by expression of the
DN mutant when needed. So, comparable to the temperature sensitive mutants the DN
mutant can be generated and investigated using one construct. This principle was utilised
for investigation of the function of M94.
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1.3 The M94 gene of murine cytomegalovirus
M94 belongs to the 43 core genes of MCMV [23] and is located in gene block 6 (Fig. 1.2),
consequently it is conserved in all Herpesviridae. Studies on M94 itself are highly limited,
only one study identified M94 as virion associated [41].
Despite the sparse publications on M94, there have been several studies on its homologues
UL94 in HCMV and UL16 in HSV, revealing several similarities. Both homologues have
been identified as virion components and as true late genes, thus depending on viral genome
replication [63, 95]. The overall sequence similarity in the homologues is low, but 7 cys-
teines are highly conserved in all Herpesviridae [64]. The exact function of these cysteines
is unknown, but they seem to be involved in different binding activities.
The interaction between pUL16 and pUL11 has been already shown in 2003 [45] and
recently the same interaction has been demonstrated for the pUL94 with pUL99, the ho-
mologue of pUL11 in HCMV [43]. Despite deletions of multiple parts of UL16/UL94, a
discrete binding site for pUL11/pUL99 could not be identified [43, 96], although Yeh et
al. could show that the interaction takes place in absence of viral or cellular partners [96].
However, blocking of the cysteines in pUL16 inhibits the binding to pUL11 [96]. Also two
studies identified the cysteines as necessary for transient capsid binding of pUL16 [53,96].
The main difference is the fact, that UL16 and homologues of α-Herpesvirinae are dispens-
able for virus replication in cell culture [3], whereas UL94 and homologues, as M94 itself,
are essential in β-Herpesvirinae [25]. Consequently in this study an essential viral function
of β-Herpesvirinae was investigated, which is absent in α-Herpesvirinae.
1.4 Aims of this study
As mentioned before, M94 is conserved in all Herpesviridae. The study of the conserved
genes is of special interest as the analysis of a single gene provides information not only
on this single gene but also on its homologues in the different Herpesviridae. The M94
gene of MCMV presents a unique factor in this setting as the function of most core genes
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is already known [24]. The fact that M94 is essential in β-Herpesvirinae but not in α-
Herpesvirinae makes this gene an interesting candidate for analysis. Thus, a detailed study
of a β-Herpesvirinae member might identify the essential function in β-Herpesvirinae and
thereby also contribute information to its function in α-Herpesvirinae.
The investigation of a deletion mutant typically results in a complex phenotype as most
viral proteins are multifunctional. Analysis of a DN mutant phenotype is more subtle as
this maintains at least one protein function intact namely to interact with at least some of
its partner proteins. Other functions are lost and define the DN phenotype.
Therefore, the aim of this study was, next to the investigation of the deletion mutant, the
identification of a DN mutant of M94 for analysis of its function in the MCMV life cycle.
In order to do this, a random mutant library was constructed by Tn7-transposon insertion
covering M94. The library was analysed by introduction into the virus context. This
defined essential regions in M94 and also essential regions, which by insertin mutagenesis
gave rise to DN mutants. The parallel investigation of deletion mutants and DN mutants
provided insight into the function of M94.
Chapter 2
Materials and Methods
2.1 Material
2.1.1 Devices
Bacterial shaker ISF-1-W Ku¨hner, Adolf AG, Birsfelden, CH
Bacterial shaker Certomat R© BS-1 Sartorius, Go¨ttingen, D
Biofuge pico Heraeus, Hanau, D
Bio-Photometer Eppendorf, Hamburg, D
CASY R© cell counter Scha¨rfe System, Reutlingen, D
Centrifuge Avanti
TM
J-20 XP Beckman Coulter, Krefeld, D
Centrifuge Evolution RC Sorvall, Waltham, MA, USA
Crosslinker BLX-254 MS Laborgera¨te, Wiesloch, D
Developing machine Optimax TR MS Laborgera¨te, Wiesloch, D
Econo-Submarine Electrophoresis System C.B.S., Del Mar, CA, USA
Electrophoresis Power Supply EPS 1001 Amersham Pharmacia Biotech,
Freiburg, D
Electrophoresis Power Supply EPS 200 Pharmacia Biotech, Freiburg, D
GeneAmp R© PCR System 9700 Applied Biosystems, Foster City, CA,
USA
Gene Pulser
TM
Bio-Rad, Mu¨nchen, D
Hybridisation Oven 612 UniEQuip, Martinsried, D
Incubater B5050E Heraeus, Hanau, D
Incubator BB16CU Heraeus, Hanau, D
Light microscope Axiovert 25 Carl Zeiss, Jena, D
Mini-PROTEAN R© 3 Cell Bio-Rad, Mu¨nchen, D
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Multifuge 3 S-R Heraeus, Hanau, D
NanoDrop
TM
ND-1000 Spectrophotome-
ter
Peqlab, Erlangen, D
Optima
TM
L-80 XP Ultracentrifuge Beckman Coulter, Krefeld, D
PCR machine TGradient Biometra, Go¨ttingen, D
pH meter 430 Corning, Miami, FL, USA
Photo documentation apparatus (Eagle
Eye)
Bio-Rad, Mu¨nchen, D
Roller mixer SRT1 Stuart, Staffordshire, UK
Shaker Swip Edmund Bu¨hler, Hechingen, D
Thermomixer 5436 Eppendorf, Hamburg, D
Tissue cell culture lamina flow BDK, Sonnenbu¨hl-Genkingen, D
Trans-Blot
TM
SD Semi-Dry Eletrophoretic
Transfer cell
Bio-Rad, Mu¨nchen, D
Typhoon 9400 Amersham Bioscience, Freiburg, D
Vortex Mixer Bender/Hobein, Bruchsal, D
Water Bath F10 Julabo, Seelbach, D
Water Bath GFL 1002 GLF, Burgwedel, D
2.1.2 Consumables
Cell culture dishes (15 cm, 10 cm, 6 cm) Becton Dickinson, Heidelberg, D
Cell culture well plates (6-, 12-, 24-, 48-,
96-well)
Becton Dickinson, Heidelberg, D
Cell scrapers (25 cm, 39 cm) Sarstedt, Nu¨mbrecht, D
Chemiluminescence Hyperfilm
TM
ECL Amersham Bioscience, Freiburg, D
Combitips plus (2.5 ml, 5 ml, 10 ml) Eppendorf, Hamburg, D
CryoTube
TM
Vials nunc, Langenselbold, D
Cuvettes Brand, Wertheim, D
Dishes Greiner Bio-one, Kremsmu¨nster, A
Electroporation cuvettes Bio-Rad, Mu¨nchen, D
Falcons conical tubes (15 ml, 50 ml) Becton Dickinson, Heidelberg, D
Inoculation loops nunc, Langenselbold, D
Medical X-Ray screen film CEA, Hamburg, D
PCR Softstrips Biozym, Oldendorf, D
Pipettes (2 ml, 5 ml, 10 ml, 25 ml) Sarstedt, Nu¨mbrecht, D
Reaction tubes (0.5 ml, 1.5 ml, 2 ml) Eppendorf, Hamburg, D
SafeSeal-Tips R© Biozym, Oldendorf, D
Ultracentrifugation tubes Beckman Coulter, Krefeld, D
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2.1.3 Reagents
Agarose Invitrogen, Karlsruhe, D
Ammonium persulfate (APS) Sigma-Aldrich, Taufkirchen, D
Ampicillin (Amp) Sigma-Aldrich, Taufkirchen, D
Bacto
TM
Agar Becton Dickinson, Heidelberg, D
Bacto
TM
Tryptone Becton Dickinson, Heidelberg, D
Bacto
TM
Yeast Extract Becton Dickinson, Heidelberg, D
BenchMark
TM
Prestained Protein Ladder Invitrogen, Karlsruhe, D
Boric acid Roth, Karlsruhe, D
Bromphenolblue Sigma-Aldrich, Taufkirchen, D
Calcium chloride Sigma-Aldrich, Taufkirchen, D
Carboxymethylcellulose, sodium salt 400-
800 cps
Sigma-Aldrich, Taufkirchen, D
Chloramphenicol (Cam) Sigma-Aldrich, Taufkirchen, D
Crystal violet Merck, Darmstadt, D
Dimethyl sulfoxide (DMSO) Merck, Darmstadt, D
DNA ladder (100 bp, 1 kbp) NEB, Ipswich, MA, USA
Doxycycline (Dox) hydrochloride Sigma-Aldrich, Taufkirchen, D
Ethanol Merck, Darmstadt, D
Ethidium bromide (EtBr) Roth, Karlsruhe, D
Ethylenediaminetetraacetic acid (EDTA) VWR, Darmstadt, D
Ficoll 400 Pharmacia Fine Chemicals, Uppsala, S
Formaldehyde Merck, Darmstadt, D
Glucose Merck, Darmstadt, D
Glycerol Roth, Karlsruhe, D
Glycine Roth, Karlsruhe, D
HEPES Fluka, Taufkirchen, D
Hydrochloric acid Roth, Karlsruhe, D
Isopropanol (2-propanol) Merck, Darmstadt, D
Kanamycin (Kan) Sigma-Aldrich, Taufkirchen, D
L-Arabinose Sigma-Aldrich, Taufkirchen, D
Maleic acid Sigma-Aldrich, Taufkirchen, D
Manganese chloride Sigma-Aldrich, Taufkirchen, D
β-Mercaptoethanol Sigma-Aldrich, Taufkirchen, D
Methanol Merck, Darmstadt, D
MOPS Roth, Karlsruhe, D
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N,N,N’,N’-Tetramethylethylenediamine
(TEMED)
Roth, Karlsruhe, D
Orange G Sigma-Aldrich, Taufkirchen, D
Phenol red Merck, Darmstadt, D
Phosphono acetic acid (PAA) Sigma-Aldrich, Taufkirchen, D
Potassium acetate Merck, Darmstadt, D
Potassium chloride Merck, Darmstadt, D
Potassium hydrogenphosphate Merck, Darmstadt, D
RNase Sigma-Aldrich, Taufkirchen, D
Roti R©-Phenol/C/I (Phenol/Chloroform/
Isoamylalcohol 25/24/1)
Roth, Karlsruhe, D
Rotiphorese R© Gel 30 (Acrylamid-bis-
acrylamid 37.5:1)
Roth, Karlsruhe, D
Rubidium chloride Sigma-Aldrich, Taufkirchen, D
D(+)-Saccharose Roth, Karlsruhe, D
Skim milk powder Merck, Darmstadt, D
Sodium acetate Merck, Darmstadt, D
Sodium chloride Merck, Darmstadt, D
Sodium citrate Roth, Karlsruhe, D
Sodium dodecyl sulfate (SDS) Roth, Karlsruhe, D
Sodium hydroxide Fluka, Taufkirchen, D
SuperFect R© Qiagen, Hilden, D
Tris Roth, Karlsruhe, D
Tween20 Sigma-Aldrich, Taufkirchen, D
Urea Fluka, Taufkirchen, D
Zeocin (Zeo) Sigma-Aldrich, Taufkirchen, D
2.1.4 Commercially kits
DIG Easy Hyb Granules Roche, Mannheim, D
DIG Luminescent Detection Kit Roche, Mannheim, D
DNeasy
TM
Blood & Tissue Kit Qiagen, Hilden, D
ECL Plus Western Blotting Detection
Reagents
GE Healthcare, Freiburg, D
Expand High Fidelity PCR System Roche, Mannheim, D
GPS R©-LS Linker scanning system NEB, Ipswich, MA, USA
GFX PCR DNA and Gel Band Purifica-
tion Kit
GE Healthcare, Freiburg, D
GFX Micro Plasmid Prep Kit Amersham Bioscience, Freiburg, D
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NucleoBond
TM
Xtra Midi Kit Macherey-Nagel, Du¨ren, D
NucleoBond
TM
PC100 Macherey-Nagle, Du¨ren, D
PCR DIG Probe Synthesis Kit Roche, Mannheim, D
QIAEX II DNA Extraction from Agarose
Gels
Qiagen, Hilden, D
2.1.5 Bacteria
E. coli strain Genotype
DH10B F− mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 recA1
endA1 araD139 ∆(ara, leu)7697 galU galKλ− rpsL nupG (Invitrogen,
Karlsruhe, D)
PIR1 F− ∆lac169 rpoS(Am) robA1 creC510 hsdR514 endA recA1
uidA(∆MluI)::pir -116 (Invitrogen, Karlsruhe, D)
Xl1-blue endA1 supE44 thi -1 hsdR17 gyrA96 relA1 lac [F′ proAB lacIqZ∆M15
Tn10 (Tetr)] (Stratagene, La Jolla, CA, USA)
2.1.6 Cells
Cell type Description
293 human embryonic kidney cells transformed with adenovirus 5, ATCC R©
number: CRL-1573
M2-10B4 bone marrow stromal cells from (C57BL/6J X C3H/HeJ)F1 mouse,
ATCC R© number: CRL-1972
MEF murine embryonal fibroblast of BALB/c-mouse [81]
NIH3T3 mouse embryonic fibroblast cell line from NIH Swiss mouse, ATCC R©
number: CRL-1658
NTM94 NIH3T3 cells mutated by Tet-Off
TM
-System (Clontech) as transcom-
plementing cell line for M94 deletion mutant
2.1.6.1 Cell culture reagents
All reagents were received from Invitrogen.
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DMEM (Dulbeccos Modified Eagle Medium) +4.5 g/l glucose, +L-glutamine, -pyruvate
RPMI (Roswell Park Memorial Institute) +L-glutamine
DPBS (Dulbeccos Phosphate Buffered Saline) -CaCl2, -MgCl2
FBS (Foetal Bovine Serum)
Hygromycin B 50 mg/ml in PBS
L-Glutamine (Q) 100x
MEM (Minimal Essential Medium) +Earles, -L-glutamine, -NaHCO3
NEAA (Non-Essential Amino Acids) 100x
NCS (Newborn Calf Serum)
Penicillin Streptomycin (P/S) 10000 units/ml penicillin, 10000 µg/ml
streptomycin
Sodium pyruvate (NaHCO3) 100 mM
Trypsin-EDTA 0.25 % Trypsin-EDTA
2.1.7 Plasmids and bacterial artificial chromosomes
The following tables summarise the plasmids and BACs used in this study and give a short
introduction in their function.
2.1.7.1 Commercial available plasmids
Name Replication
ability,
temper-
ature,
antibiotic
resistance
Description
Litmus28 DH10B,
37◦C, Amp
Cloning vector from NEB
pGPS4 PIR1,
37◦C, Cam
Donor vector in transposon mutagenesis (GPS R©-LS Linker
scanning system)
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2.1.7.2 Available plasmids in the lab
Name Replication
ability,
temper-
ature,
antibiotic
resistance
Description
pSM3fr-FRT DH10B,
37◦C, Cam
complete MCMV genome as BAC including FRT site be-
tween genes m16 and m17 ( [10])
pKD46 DH10B,
30◦C, Amp
expresses recombinases α, β, and γ from λ phage for BAC
ET-cloning ( [22])
pCP20 DH10B,
30◦C,
Amp, Cam
expresses Flp recombinase for BAC mutagenesis ( [15])
pGPS1.1 PIR1,
37◦C, Kan
template vector for PCR for BAC mutagenesis
pOriR6K-ie PIR1,
37◦C, Zeo
expression vector for subcloning in transposon mutagen-
esis containing FRT site for ectopic insertion into BACs
(GenBank: AY700021.1)
pOriR6K-ie-
HAM94
PIR1,
37◦C, Zeo
HA-tagged M94 under control of HCMV immediate early
promoter enhancer in pOriR6K-ie
pSM3fr∆M94 DH10B,
37◦C,
Cam, Kan
MCMV genome deleted in M94 replaced by kanamycin re-
sistance
pSM3fr∆M94-
EPM94
DH10B,
37◦C,
Cam, Kan,
Zeo
rescue of pSM3fr∆M94 by ectopic insertion of M94 under
control of its endogenous promoter
pO6CMV PIR1,
37◦C, Zeo
conditional expression cassette including HCMV immedi-
ate early promoter enhancer for expression of mutants in
pOriR6K-ie vector ( [77])
pO6SVT PIR1,
37◦C, Zeo
conditional expression cassette including SVT40 early en-
hancer for expression of mutants in pOriR6K-ie vector
( [77])
pSM3fr-FRT-
∆1-16
DH10B,
37◦C, Cam
MCMV genome deleted in genes m01 to m16 including
FRT site between genes m16 and m17
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2.1.7.3 Cloned plasmids
Name Replication
ability,
temper-
ature,
antibiotic
resistance
Description
Litmus28-
HAM94
DH10B,
37◦C, Amp
HA-M94 subcloned from pOriR6K-ie-HAM94 into Litmus
28 (section 3.3)
pSM3fr∆M94-
EHAM94
DH10B,
37◦C,
Cam, Kan,
Zeo
rescue of pSM3fr∆M94 by ectopic insertion of HA-M94
(pOriR6K-ie-HAM94) under control of HCMV immediate
early promoter enhancer
pOriR6K-ie-
mLM94i7
PIR1,
37◦C, Zeo
DN mutant M94i7 resulting from transposon mutagenesis
and subsequent subcloning under control of HCMV imme-
diate early promoter enhancer in pOriR6K-ie
pOriR6K-ie-
mLM94i13
PIR1,
37◦C, Zeo
DN mutant M94i13 resulting from transposon mutagenesis
and subsequent subcloning under control of HCMV imme-
diate early promoter enhancer in pOriR6K-ie
pO6CMV-
M94i7
PIR1,
37◦C, Zeo
DN mutant M94i7 subcloned from pOriR6K-ie-mLM94i7
by PCR using primers M94-Mlu1-for and M94-Pvu2-rev
and subsequent restriction with MluI and PvuII into
pO6CMV digested with AscI and HpaI for conditional ex-
pression
pO6CMV-
M94i13
PIR1,
37◦C, Zeo
DN mutant M94i13 subcloned as described for pO6CMV-
M94i7
pO6SVT-
M94i7
PIR1,
37◦C, Zeo
DN mutant M94i7 subcloned from pOriR6K-ie-mLM94i7
by PCR using primers M94-Mlu1-for and M94-Pvu2-rev
and subsequent restriction with MluI and PvuII into
pO6SVT digested with AscI and HpaI for conditional ex-
pression
pO6SVT-
M94i13
PIR1,
37◦C, Zeo
DN mutant M94i13 subcloned as described for pO6SVT-
M94i7
pSM3frCMV-
RM94i7
DH10B,
37◦C,
Cam, Zeo
pO6CMV-M94i7 ectopically inserted via Flp-FRT system
into pSM3fr-FRT
pSM3frCMV-
RM94i13
DH10B,
37◦C,
Cam, Zeo
pO6CMV-M94i13 ectopically inserted via Flp-FRT system
into pSM3fr-FRT
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pSM3frSVT-
RM94i7
DH10B,
37◦C,
Cam, Zeo
pO6SVT-M94i7 ectopically inserted via Flp-FRT system
into pSM3fr-FRT
pSM3frSVT-
RM94i13
DH10B,
37◦C,
Cam, Zeo
pO6SVT-M94i13 ectopically inserted via Flp-FRT system
into pSM3fr-FRT
pSM3fr∆1-
16CMV-
RM94i7
DH10B,
37◦C,
Cam, Zeo
pO6CMV-M94i7 ectopically inserted via Flp-FRT system
into pSM3fr-FRT-∆1-16
pSM3fr∆1-
16CMV-
RM94i13
DH10B,
37◦C,
Cam, Zeo
pO6CMV-M94i13 ectopically inserted via Flp-FRT system
into pSM3fr-FRT-∆1-16
pSM3fr∆1-
16SVT-
RM94i7
DH10B,
37◦C,
Cam, Zeo
pO6SVT-M94i7 ectopically inserted via Flp-FRT system
into pSM3fr-FRT-∆1-16
pSM3fr∆1-
16SVT-
RM94i13
DH10B,
37◦C,
Cam, Zeo
pO6SVT-M94i13 ectopically inserted via Flp-FRT system
into pSM3fr-FRT-∆1-16
pSM3fr∆1-
16-EHAM94
DH10B,
37◦C,
Cam, Zeo
HA-M94 (pOriR6K-ie-HAM94) under control of HCMV
immediate early promoter enhancer ectopically inserted
into pSM3fr-FRT-∆1-16 as overexpressing control in
Southern blot analysis
pO6SVT-
HAM94
PIR1,
37◦C, Zeo
HAM94 subcloned from pOriR6K-ie-HAM94 by PCR us-
ing primers HAM94-Asc-for and HAM94-Sma-rev and sub-
sequent restriction with AscI and SmaI into pO6SVT di-
gested with AscI and HpaI for conditional expression
pSM3fr∆1-
16SVT-
RHAM94
DH10B,
37◦C,
Cam, Zeo
HA-M94 (pO6SVT-HAM94) under control of inducible
SVT40 early enhancer ectopically inserted into pSM3fr-
FRT-∆1-16 as overexpressing control in western blot anal-
ysis
2.1.8 Oligonucleotides
Oligonucleotides were synthesised by Metabion, whereas primers for sequencing were pro-
vided by GATC Biotech.
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Name Sequence (5′ → 3′) Comment
M94-Mlu1-
for
GTGTACGCGTACCATGTACCCC
TACGACGTGCCC
forward primer for subcloning of
M94i7 and M94i13 into pO6CMV and
pO6SVT
M94-
Pvu2-rev
ACACCAGCTGTCGACTTCACAT
GTGCTCGAGAAC
reverse primer for subcloning of
M94i7 and M94i13 into pO6CMV and
pO6SVT
HAM94-
Asc-for
GGTGGCGCGCCTCACTATAGGG
AGACCCAAGCT
forward primer for subcloning of HA-
M94 into pO6SVT
HAM94-
Sma-rev
GTGGCCCGGGAGAGTCGACTTC
ACATGTGCTC
reverse primer for subcloning of HA-
M94 into pO6SVT
Apa2-for ATCGGGTCACAGTCCTCACGCC forward primer for generation of
Southern probe for Southern blot
analysis on MCMV∆1-16
Apa2-rev CAACATCCGTGGGTCGACACC reverse primer for generation of
Southern probe for Southern blot
analysis on MCMV∆1-16
CMV-F CGCAAATGGGCGGTAGGCGTG sequencing primer for pOriR6K,
pO6CMV and pO6SVT constructs
BGH-
Reverse
TAGAAGGCACAGTCGAGG sequencing primer for pOriR6K con-
structs
pEGFP-
FP
TTTAGTGAACCGTCAGATC sequencing primer for pO6CMV and
pO6SVT constructs
2.1.9 Viruses
Viruses used in this study were recovered from BACs mentioned in section 2.1.7 by re-
constitution (section 2.2.7.1) and labelled according to the BAC names by exchanging
”pSM3fr” with MCMV.
The virus MCMV∆M94tTA was kindly provided by Christian Mohr. The corresponding
BAC pSM3fr∆m157∆M94tTA includes the MCMV genome deleted in m157 and M94. The
non-essential gene m157 was replaced by a floxed OVA-cassette as the virus was originally
created for in vivo experiments. M94 was replaced by a tetracycline-controlled transacti-
vator (tTA) from the Tet-Off
TM
Gene Expression System (Clontech). The corresponding
tetracycline-response element (TRE) was provided by pTRE2hyg. M94 was subcloned into
this vector under control of TRE. This vector was transformed into NIH3T3 cells and se-
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lected for the inherent plasmid by hygromycin selection (section 2.2.6.1). Infection of these
cells with MCMV∆M94tTA resulted in binding of tTA from the virus to TRE in the cells,
consequently the expression of M94 in the cells was activated and provided the essential
component for viral progeny, but remained the virus genetically deleted in M94. So the
virus MCMV∆M94tTA was produced on this complementing cell line.
2.1.10 Antibodies
CROMA101
(α-pp89)
mouse monoclonal antibody provided by S. Jonjic, University of Ri-
jeka, Rijeka, Croatia
α-M50 rabbit polyclonal serum published in [61]
α-M94 A and
B
rabbit polyclonal sera produced by metabion against peptides
CMLVNKSARYREFRAV and CRDS-
GRHVDPTGRFV
α-HA-
Peroxidase
High Affinity
rat monoclonal antibody
conjugated to peroxidase
purchased by Roche
Secondary antibodies were coupled to horseradish peroxidase (HRP) and purchased from
Dianova.
anti-mouse IgG (H+L) HRP coupled
anti-rabbit IgG (H+L) HRP coupled
anti-rat IgG (H+L) HRP coupled
2.2 Methods
2.2.1 Bacterial cell culture
The bacterial strains DH10B and PIR1 (section 2.1.5) were grown in LB media either in
liquid culture or on LB agar plates at 37◦C or 30◦C depending on the comprising plasmid.
The bacterial strain XL1blue (section 2.1.5) was cultured in SOC media at 37◦C. Plasmid
maintenance was guaranteed by maximal selection pressure through addition of antibiotics,
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except the combination of Cam and Zeo, which was not applied in liquid culture as this
combination inhibited bacterial growth unspecifically. Cell density was determined by
measurement of the optical density (OD) of a liquid culture at OD600.
LB medium SOC medium
10 g Bacto
TM
Tryptone 20 g Bacto
TM
Tryptone
5 g Bacto
TM
Yeast Extract 5 g Bacto
TM
Yeast Extract
4 g sodium chloride 0.5 g sodium chloride
add 1 l 20 mM glucose
add 1 l
LB Agar Antibiotics (stock/final concentration)
7.5 Bacto
TM
Agar Amp 100 mg/ml 100 µg/ml
add 500 ml LB medium Kan 100 mg/ml 50 µg/ml
Cam 25mg/ml 25 µg/ml
Zeo 100mg/ml 30 µg/ml
2.2.1.1 Preparation of chemocompetent bacteria
All steps were performed at 4◦C or on ice using pre-cooled pipettes, flasks and solutions.
50 ml LB media containing antibiotics were inoculated with 1 ml overnight culture and
grown at either 30◦C or 37◦C up to an OD600 of 0.5. The culture was chilled on ice for
5 min and bacteria collected by centrifugation (2,600 g, 15 min, 4◦C). The supernatant was
discarded, the pellet resuspended in 10 ml TfBI-buffer and incubated on ice for 50 min.
After centrifugation of the bacteria (2,600 g, 15 min, 4◦C), the pellet was resuspended
in 1 ml TfBII-buffer and aliquots of 100 µl were snap frozen in liquid nitrogen before
transferred to -80◦C storage.
TfBI-buffer TfBII-buffer
100 mM RbCl2 10 mM MOPS pH 7.0
50 mM MnCl2 10 mM RbCl2
30 mM KAc 75 mM CaCl2
10 mM CaCl2 15 % glycerol
pH 5.8 pH 7.0
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2.2.1.2 Transformation of chemocompetent bacteria
For transformation of chemocompetent bacteria, aliquots were thawed on ice and 10 ng of
plasmid DNA was added. This reaction was incubated on ice for 30 min and subsequently
heat shocked for 45 sec at 42◦C, before chilled on ice for 2 min. 1 ml LB media without
antibiotics was added and the culture incubated for 1 h at the appropriate temperature.
About 100 µl of the culture were plated on LB agar plates containing the corresponding
antibiotics.
2.2.1.3 Preparation of electrocompetent bacteria
The preparation of electrocompetent bacteria was performed on ice using pre-cooled pipettes,
flasks and solutions. 400 ml LB media containing antibiotics were inoculated with 1.5 ml
overnight culture and grown at 37◦C up to OD600 of 0.5. The culture was incubated on
ice for 30 min and bacteria were pelleted by centrifugation (5,500 g, 10 min, 4◦C). After
discarding the supernatant, the pellet was resuspended in 200 ml water. Centrifugation
was repeated and the bacteria resuspended in 5 % glycerol. This step was repeated once,
followed by an additional washing in 10 % glycerol. The pellet was then resuspended in
2 ml 10 % glycerol and aliquots of 50 µl were snap frozen in liquid nitrogen and stored at
-80◦C.
2.2.1.4 Transformation of electrocompetent bacteria
For transformation of electrocompetent bacteria, aliquots were thawed on ice, 10-50 ng of
plasmid DNA were added and this mixture was transferred into a pre-cooled electroporation
cuvette (diameter 2 mm). The electroporation was performed at a 2.5 kV, resistance of
200 Ω, and a capacitance of 25 µF. The bacteria were immediately transferred into 1 ml
LB media without antibiotics and grown for 1 h at 37◦C. Subsequently 100 µl were plated
on antibiotic containing LB agar plates.
2.2 Methods 27
2.2.1.5 Preparation of glycerol stocks
Bacteria containing cloned plasmids or BACs were stored as glycerol stocks at -80◦C. To
this end 600 µl of overnight culture were mixed with 400 µl of 50 % glycerol and transferred
to -80◦C.
2.2.2 Isolation and purification of DNA
Isolated DNA was dissolved in Tris-HCl buffer (T-buffer) and stored at -20◦C. Centrifu-
gations including volumes up to 2 ml were performed in Heraeus Biofuge pico, whereas
cultures up to 50 ml were collected in Heraeus Multifuge 3 and larger volumes were pro-
cessed in Sorvall Evolution RC. All steps were accomplished at room temperature (RT)
except as noted otherwise.
T-buffer: 10 mM Tris/HCl pH 8.0
2.2.2.1 Small scale isolation of plasmid DNA
Small scale isolation of high and low copy plasmid DNA was performed using GFX Micro
Plasmid Prep Kit from Amersham Bioscience. An overnight culture of 2 ml was treated
according to manufacturers purification from 1-1.5 ml culture protocol.
2.2.2.2 Large scale isolation of plasmid DNA
Large scale isolation of plasmid DNA was accomplished by NucleoBond
TM
Xtra Midi Kit
from Macherey-Nagel. Commonly 150 ml of overnight culture grown in LB media con-
taining antibiotics were treated according to manual for high copy plasmid purification.
Purified DNA was dissolved in 200-500 µl T-buffer.
2.2.2.3 Small scale isolation of BAC DNA
A 10 ml overnight culture was collected by centrifugation (2,600 g, 15 min, RT), the pellet
resuspended in 300 µl Resuspension buffer, and transferred to 2 ml reaction tubes. 300 µl
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Lysis buffer were added and samples inverted several times. Next 300 µl of Neutralisation
buffer were added and samples inverted several times again. The lysates were then incu-
bated 10 min one ice and cleared by centrifugation (20,000 g, 5 min, RT). The supernatant
was transferred into a new reaction tube and 1 ml Roti R©-Phenol/C/I (Roth) was added.
The samples were incubated on roller shaker for at least 10 min for protein extraction. The
aqueous phase was regained by centrifugation (20,000 g, 5 min, RT) and transferred into a
new reaction tube. 1 ml isopropanol was added for DNA precipitation. After proper mix-
ing, the DNA was collected by centrifugation (20,000 g, 30 min, RT). After discarding the
supernatant, the DNA pellet was washed by adding 1 ml 70 % ethanol and centrifugation
(20,000 g, 10 min, RT). The DNA pellet was dried at 45◦C for 5-15 min and resuspended
in 50 µl T-buffer including 100 µg/ml RNase. This procedure yielded material for a single
restriction analysis.
Resuspension buffer Lysis buffer Neutralisation buffer
50 mM Tris/HCl, pH 8.0 200 mM NaOH 3 M KAc, pH 4.8
10 mM EDTA 1 % (w/v) SDS
100 µg/ml RNase
2.2.2.4 Large scale isolation of BAC DNA
For large scale isolation of BAC DNA NucleoBond
TM
Xtra Midi Kit from Macherey-Nagel
was utilised. The protocol for low-copy plasmid purification provided by manufacturers
was modified by using 10 ml of buffers RES, LYS and NEU instead of 16 ml. Otherwise
the protocol was performed as described. The DNA pellet was dissolved in 100 µl T-buffer.
For handling of BAC DNA solution pipette tips with extended cut were used.
2.2.2.5 Concentration of DNA by ethanol precipitation
The solution containing the DNA was drugged with 1
10
(v/v) 3 M sodium acetate and
threefold volume of pure ethanol. The reaction was incubated at -80◦C for 20 min and
the precipitated DNA collected by centrifugation (20,000 g, 5 min, 4◦C). The pellet was
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washed by adding 200 µl of 70 % ethanol and centrifugation (20,000 g, 5 min, 4◦C). After
air drying of the pellet, it was resuspended in 10 µl T-buffer.
2.2.2.6 Isolation of DNA from cell culture
DNA was isolated from cells by using DNeasy
TM
Blood & Tissue Kit from Qiagen. The pro-
cedure ”Purification of Total DNA from Animal Blood or Cells (Spin-Column Protocol)”
was complied according to the manual.
2.2.2.7 Determination of DNA concentration
The concentration of isolated DNA was determined by spectral measurement with NanoDrop
TM
micro spectrophotometer by the manufacturers standard protocol given.
2.2.3 Analysis and cloning of DNA
2.2.3.1 Polymerase chain reaction
For the in vitro amplification of DNA the PCR was utilised. As the PCR was required
for several experiments, the composition and conditions are listed below separately. The
reactions were setup on ice in the indicated order.
PCR for cloning
H2O add 50 µl 94
◦C 5 min
10x buffer no.2 1x 94◦C 30 sec 20 cycles
dNTP mix (10 mM) 200 µM 62-52◦C 30 sec 20 cycles
for primer (10 µM) 300 nM 72◦C 1 min/1000 bp 20 cycles
rev primer (10 µM) 300 nM 94◦C 30 sec 20 cycles
template (10 ng/µl) 1 ng/µl 50◦C 30 sec 20 cycles
High Fidelity polymerase 1 unit 72◦C 1 min/ 1000 bp 20 cycles
72◦C 3 min
4◦C ∞
Reagents for cloning PCR were purchased from Expand High Fidelity PCR system from
Roche. In this touch down PCR the annealing temperature dropped 0.5◦C in every cycle
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automatically due to the setting of the TGradient PCR machine from Biometra.
PCR for BAC mutagenesis
H2O add 100 µl 95
◦C 5 min
10x buffer no.2 1x 95◦C 30 sec 17 cycles
dNTP mix (10 mM) 200 µM 62-45◦C 30 sec 17 cycles
for primer (10 µM) 300 nM 72◦C 1 min/1000 bp 17 cycles
rev primer (10 µM) 300 nM 95◦C 30 sec 18 cycles
template (10 ng/µl) 1 ng/µl 45◦C 30 sec 18 cycles
High Fidelity polymerase 1 unit 72◦C 1 min/ 1000 bp 18 cycles
72◦C 5 min
4◦C ∞
For the BAC mutagenesis PCR the reagents from the Expand High Fidelity PCR system
from Roche were used. The temperature in this touch down PCR dropped by 1◦C each
cycle by using the same PCR machine as in the cloning PCR.
PCR for generation of Southern probe
H2O add 50 µl 94
◦C 5 min
10x buffer vial 3 1x 94◦C 30 sec 20 cycles
dNTP mix (10 mM) vial 2/4 200 µM 65-45◦C 30 sec 20 cycles
for primer (10 µM) 300 nM 72◦C 1 min/1000 bp 20 cycles
rev primer (10 µM) 300 nM 94◦C 30 sec 28 cycles
template (10 ng/µl) 1 ng/µl 45◦C 30 sec 28 cycles
High Fidelity polymerase 1 unit 72◦C 1 min/ 1000 bp 28 cycles
72◦C 7 min
4◦C ∞
For the generation of the Southern probe the reagents contained in the PCR DIG Probe
Synthesis Kit from Roche were applied. The control PCR without Dig labelling contained
dNTP mix vial 4, whereas the PCR with Dig labelling included vial 2 containing Dig
labelled NTPs. In this touch down PCR the temperature dropped 1◦C in each cycle, using
the GeneAmp
TM
PCR System 9700 from Applied Biosystems.
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2.2.3.2 Buffer change of PCR products
Digested DNA were prepared for ligation by buffer change using GFX PCR DNA and
Gel Band Purification Kit from GE Healthcare according to manufacturers protocol for
purification of DNA from solutions. DNA was eluted by two sequential applications of
20 µl of T-buffer.
2.2.3.3 Restriction enzyme digest of DNA
Restriction enzymes from New England Biolabs (NEB) or Fermentas were used according
to manual with 10 units of enzyme for each digest, supplemented with 1x buffer, and 1
100
volume of BSA as needed. For digestion with two enzymes either a buffer permitting 100 %
restriction efficiency for both enzymes was selcted from the companies buffer set or a sequel
digest was applied.
Analytic digestion of plasmid DNA was performed in 20 µl final volume including 5 µl of
the small scale preparation for 1 h at the appropriate temperature. Whereas for preparative
digestion were carried out in up to 80 µl final volume and at least 3 h at the appropriate
temperature. Analytic digestion of BAC DNA was performed in 60 µl final volume for
small scale preparations including the entire isolate and in 40 µl for large scale isolates
containing 1.5 µg DNA for 2-3 h at the appropriate temperature.
2.2.3.4 Dephosphorylation of DNA
Digested DNA was dephosphorylated by Antarctic Phosphatase from NEB following the
manual.
2.2.3.5 Blunting of DNA fragments by DNA polymerase
DNA overhangs were either filled (5′overhangs) or removed (3′overhangs) via DNA Poly-
merase Large (Klenow) Fragment from NEB. Conditions were used according to manufac-
turers protocol.
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2.2.3.6 Agarose gel electrophoresis
Digested DNA was supplemented with 1
5
volume of loading buffer and separated on non
denaturating agarose gels of 1 % (w/v) for plasmid DNA and 0.8 % (w/v) for BAC DNA.
Ethidium bromide was added to final concentration of 1 µg/ml to the gels and for analysis
of BACs ethidium bromide was also added to the buffer. The agarose gels for analysis of
plasmids were prepared with and separated in TAE buffer, whereas TBE buffer was used
for analysis of BACs. Agarose gel electrophoresis was performed at constant voltage of 5
V/cm for up to 1 h in case of plasmids and at 80 V for 16-24 h for BACs. The resulting
banding pattern were then visualised by UV light on Eagle Eye imager from Bio-Rad.
TAE (50x) TBE (10x) Loading buffer (6x)
2 M Tris 900 mM Tris 15 % (w/v) Ficoll
250 mM sodium acetate 900 mM boric acid 0.25 % (w/v) Orange G
50 mM EDTA 10 mM EDTA
pH 7.3 pH 8.0
2.2.3.7 Isolation of DNA fragments from agarose gels
DNA fragments were isolated from agarose gels by using ”QIAEX II DNA Extraction from
Agarose Gels” Kit from Qiagen according manufacturers instructions.
2.2.3.8 Ligation of DNA fragments
The vector, containing the origin of replication and the antibiotic resistance, and the
subcloned fragment, the insert were ligated by mixing 100 ng vector with threefold molar
ratio of insert and 20 units T4 DNA Ligase (NEB) and corresponding buffer in a final
volume of 20 µl and incubated at 16◦C overnight. Bacteria were transformed with 1
10
of
this reaction.
2.2.3.9 Sequencing of DNA
Successful cloning of DNA constructs was verified by sequencing. Plasmid DNA was se-
quenced by GATC Biotech (Konstanz, D) and BAC DNA by Sequiserve (Vaterstetten, D).
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The resulting sequences were aligned and compared using Vector NTI Advance
TM
Software.
2.2.4 Transposon mutagenesis
The HA-tagged M94 was subcloned from pOriR6K-ie-HAM94 (section 2.1.7) into Lit-
mus28, as this contained no PmeI restriction site and no chloramphenicol resistance and
could replicate in bacteria other than PIR1. The detailed cloning is described in section
3.3.
The transposon reaction was performed in vitro using the GPS R©-LS Linker Scanning sys-
tem (NEB) according to the manual (Tab. 4.1). XL1-blue bacteria, supplied by Stratagene
with warranty of sufficient transformation efficiency, were transformed with 2 µl of this
reaction according to the manufacturers instructions. The transformants were incubated
in 1 ml SOC medium without antibiotics for 1 h at 37◦C and 100 µl of a 1:10 dilution of
this culture was plated on LB agar plates containing Amp and Cam.
The size of the library was estimated by the number of streaked colonies and 20 clones
were analysed to shown the efficiency of transprimer insertions into Litmus28-HAM94 by
restriction with Acc65I and NsiI, cleaving HA-M94 and potential insertion from the vector.
As this demonstrated adequate results, the complete transformation was plated onto LB
agar plates (diameter 15 cm) in volume corresponding to the plate size and the colony
number on the trial streak. The colonies were then scraped in LB media and collected
by centrifugation (6000 g, 15 min, 4◦C). The DNA of this pool was isolated by using the
NucleoBond
TM
PC100 Kit from Macherey-Nagel. The protocol was slightly modified and
as follows.
The bacterial pellet was resuspended in 8 ml buffer S1 on ice and 8 ml of buffer S2 were
added. The solution was inverted 5 times and then incubated on ice for 5 min. Subse-
quently 8 ml of buffer S3 were added, the solution inverted 15 times, and again incubated
on ice for 5 min. The supernatant was cleared by centrifugation (17,000 g, 30 min, 4◦C),
before transferred via filter paper onto the column, which was pre-equilibrated with 2.5 ml
of buffer N2. The column flow through was harvested and transferred onto the column
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again. The column was then washed 3 times with 5 ml buffer N3. The DNA was eluted by
addition of twice 2.5 ml of 50◦C heated buffer N5. The solution was covered with 3.5 ml
isopropanol and mixed right before centrifugation (27,000 g, 30 min, 4◦C). The supernatant
was discarded immediately and 5 ml of ice-cold 70 % ethanol were added and centrifuged
(27,000 g, 10 min 4◦C). Again the supernatant was discarded immediately and the pellet
was air dried. The DNA was then resuspended in 50 µl T-buffer overnight at 4◦C.
The isolated DNA was digested by Acc65I and NsiI. Thereby HA-M94 encoding fragments
were cleaved out from the vector. The HA-M94 fragments containing a transprimer inser-
tion could be selectively isolated due to their increased size after agarose gel electrophoresis
and were purified as described (section 2.2.3.7).
The expression vector pOriR6K-ie was digested with Acc65I and NsiI and dephosphory-
lated. The transprimer marked HA-M94 encoding fragments, which were isolated from
the library, were ligated to this vector. In this ligation the vector was added in threefold
higher molar concentration compared to the library derived fragments. This increased
the chance for each individual fragment for ligation with a vector molecule. Since both
fragments contained an antibiotic resistance, remaining vector fragments could be removed
after transformation by double selection.
1
10
of this ligation was electroporated into highly competent PIR1 bacteria and 100 µl of a
1:10 dilution were plated on LB agar plates containing Cam and Zeo. By this trial plate
out, the library size was estimated and 20 clones were analysed. If this was positive, the
entired transformation was plated completely, the colonies were collected, and library DNA
isolated as described previously.
This pool of plasmids was digested with PmeI to remove the transprimer. The remaining
vector fragment was separated from the transprimer by agarose gel electrophoresis and
isolated and purified as described earlier. The isolated vector fragment was then religated
by standard ligation protocol. Again PIR1 were electroporated with a fraction of 1
10
of
the ligation and 100 µl of a 1:10 dilution were plated on LB agar plates containing Zeo.
The final size of the library was estimated. Single clones were picked and removal of the
transprimer was analysed by identification of loss of chloramphenicol resistance. The po-
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sition of the transposon insertion in HA-M94 derived from restriction analysis and finally
the mutant open reading frame (ORF) was sequenced.
2.2.5 Mutagenesis of BACs
The cloning of the MCMV genome as bacterial artificial chromosome [54] increased it
accessibility for mutagenesis strategies. However, here classical cloning methods are not
applicable due to high frequency of restriction sites and the large size of the construct. Our
laboratory adapted homologous recombination by ET cloning for mutagenesis of BACs [92].
In this process a linear DNA fragment, produced by PCR, is inserted into bacteria contain-
ing the BAC and a plasmid pKD46 [22] expressing the recombinases α, β, and γ from λ
phage. By double crossing-over with flanking homologies between the PCR fragment and
the target BAC the mutation is introduced into the MCMV BAC as illustrated in figure
2.1.
In this study, in order to verify the phenotype of a gene deletion, a rescue by reinsertion of
the deleted gene is applied. Therefore the MCMV BAC utilised in this study contained a
Flp recombinase target (FRT) site. The Flp recombinase from the 2 µm plasmid of yeast
recognises the FRT sites and mediates a specific recombination between two of these. Con-
sequently a plasmid containing the gene of interest and a FRT site is introduced ectopically
into the BAC at the position of its FRT site.
2.2.5.1 Generation of recombinant BACs
The PCR for generation of the linear DNA fragment was already specified in section 2.2.3.1
and performed using pGPS1.1 as template. After analysis of the PCR product by agarose
gel electrophoresis, the DNA was purified by buffer change (section 2.2.3.2) and subse-
quently digested with DpnI to disintegrate the template DNA. The PCR product was then
precipitated (section 2.2.2.5).
Bacteria containing the BAC for mutagenesis were prepared as chemical competent (sec-
tion 2.2.1.1) and transformed with 10 ng pKD46 (section 2.2.1.2). These bacteria were
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then utilised for preparation of electrocompetent bacteria (section 2.2.1.3) in presence of
0.1 % (w/v) L-Arabinose at 30◦C and transformed with 0.5-1.5 µg of the precipitated lin-
ear fragment at 37◦C. The resulting clones contained the mutated BACs and lost pKD46
due to its temperature sensitive origin of replication preventing a replication at 37◦C and
selection for both antibiotics. They were analysed by restiction digest.
Kan
KanH1 H2
H1 H2
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Figure 2.1: For the generation of recombinant BACs the linear DNA fragment containing the homologies (H1 and H2) is
generated by PCR. The fragment is transformed into bacteria containing the BAC and pKD46, the plasmid expressing the
recombinases, which is subsequently lost due to its temperature sensitive origin of replication.
2.2.5.2 Insertion of genes by Flp recombinase
The plasmid pCP20 was inserted into bacteria containing the BAC with the target FRT
site for insertion by chemical transformation. The resulting bacteria were then prepared
to be electrocompetent and transformed with 10-50 ng of a pOriR6K construct containing
a FRT site and the gene of interest at 30◦C. The culture was selectively plated on LB
agar plates containing Cam and Zeo and incubated at 43◦C overnight to remove pCP20
containing a temperature sensitive origin of replication. The resulting constructs were
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analysed by restriction digest for insertion of the pOriR6K construct. Occuring multiple
insertions of the vector, called double insertions, were also separated by this restriction
analysis.
30°C
43°C
FLP
BAC
BAC
FLP
Figure 2.2: For the insertion of genes by Flp recombinase, the pOriR6K construct including an FRT site is transformed into
bacteria containing the BAC and pCP20 expressing the Flp recombinase, which is subsequently lost due to its temperature
sensitive origin of replication.
2.2.6 Cell culture
2.2.6.1 Cultivation of mammalian cells
All cells were cultivated at 37◦C in presence of 5 % CO2 and 95 % humidity. Cells were
splitted in ration and frequency according to table 2.7. In order to subculture cells, they
were washed with DPBS and detached from the cell culture dish by trypsin-EDTA treat-
ment. Detached cells were resuspended in appropriated media and distributed on fresh cell
culture dishes.
2.2.6.2 Freezing of cells
For storage of cells they were frozen in media containing DMSO and stored in liquid
nitrogen. Confluent cells were detached by trypsin-EDTA treatment and collected by
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Table 2.7: Standard media for cell culture
Cell line Basic medium Additives Split/interval
293 DMEM 10 % FBS, P/S, Q 1:5/2-3 days
M2-10B4 RPMI 10 % FBS, P/S 1:6/2-3 days
MEF DMEM 10 % FBS, P/S 1:4/3-4 days
NIH3T3 DMEM 5 % NCS, P/S 1:6/2-3 days
NTM94 DMEM 5 % NCS, P/S, 50 µg/ml hygromycin 1:6/2 days
centrifugation (310 g, 5 min, RT). The cell pellet was resuspended in freezing media and
aliquoted by 1 ml in 1.8 ml freezing vials. These were transferred in boxes containing
isopropanol into -80◦C for 24 h and subsequently transferred into liquid nitrogen.
Freezing media
10 % DMSO
25 % FBS
65 % basic medium (Tab. 2.7)
2.2.6.3 Thawing of cells
Cells were thawed at 37◦C in water bath and immediately transferred into their standard
medium. To remove DMSO, cells were collected by centrifugation (310 g, 5 min, RT) and
resuspended in fresh medium, before applied on cell culture dish.
2.2.6.4 Determination of cell numbers
Numbers of detached viable cells were determined by measurement with CASY R© cell
counter from Scha¨rfe System. The cell suspension was diluted 1:100 in CASY R©-Ton and
analysed according to manufacturers instructions.
2.2.6.5 Transfection of cells using Superfect
Confluent 10 cm dish of MEF cells was splitted onto 6 of 6 cm dishes 1 day prior transfection
with SuperFect R© Transfection Reagent from Qiagen. About 1.5 µg of BAC DNA was
transferred in reaction tubes and filled by basic medium to 150 µl final volume. 10 µl
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of ice-cold SuperFect R© Transfection Reagent was added and the reaction incubated for
10-15 min after mixing. Then 1 ml standard medium was added to the DNA/SuperFect R©
mixture and this solution was transferred onto cells. After 3 h the solution was exchanged
to medium.
2.2.6.6 Transfection of cells using CaPO4 precipitation
Confluent 10 cm dish of 293 cells was splitted onto 4 of 6 cm dishes 1 day prior the
transfection. All solutions were sterile filtered and stored on ice. To 7 µg of DNA, 250 µl
of 250 mM calcium chloride were added. While mixing the solution, 250 µl of HEBS buffer
were added slowly. The reaction was incubated for 15 min and then transferred onto cells.
These were harvested after 24 h.
HEBS buffer
16 g/l NaCl
0.72 g/l KCl
0.25 g/l Na2HPO4x2H2O
10 g/l HEPES
2 g/l glucose
adjust pH 7.5 by NaOH
2.2.6.7 Application of additional cell culture reagents
Dox was prepared as 10 mg/ml stock solution in DPBS and stored at -80◦C. PAA was
prepared as 300 mg/ml stock solution in water and stored at -20◦C. Both reagents were
added 1 hpi to the cells. Dox was applied in 1 µg/ml final concentration, whereas PAA
was used in 300 µg/ml final concentration.
2.2.7 Virological methods
2.2.7.1 Virus reconstitution from BAC DNA
MEF cells were transfected with BAC DNA using SuperFect R© Transfection Reagent (sec-
tion 2.2.6.5). After 24 h cells were splitted 1:3 on 10 cm cell culture dishes.
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For production of viral inoculum, cells were subcultured again once they showed plaque
formation.
In case of analytical virus reconstitution, cell were not subcultured after plaque formation,
but time points of first plaque formation and lysis were observed. If plaque formation was
absent, cells were splitted 1:2 every second week for 6 weeks. Cultures without plaque
formation after 6 weeks were dismissed.
2.2.7.2 Infection of cells with MCMV
Cells numbers were determined (section 2.2.6.4) and appropriate cell numbers were pro-
vided in 15 ml tubes. Viral inoculum was added corresponding to the intended multiplicity
of infection (MOI) together with Dox if necessary. The infected cells were then distributed
on cell culture dishes.
2.2.7.3 Preparation of MCMV stock
M2-10B4 cells from three 15 cm cell culture dishes were harvested, infected with 10 ml
viral inoculum and distributed on 20 of 15 cm cell culture dishes. Upon 2 days after
100 % cytopathic effect cells were scraped from plates in their own media and collected
by centrifugation (5,500 g, 15 min, 4◦C). The supernatant was collected and stored on ice,
whereas the pellet was resuspended in media and homogenised by douncer. Thereby cell
associated virus was released and remaining cells were removed by centrifugation (17,000 g,
10 min, 4◦C). This supernatant was combined with the supernatant from the previous
centrifugation and viral particels were collected by centrifugation (20,000 g, 3 h, 4◦C). The
pellet was resuspended in 4 ml own media and transferred onto a 15 % sucrose cushion.
The virus particles were purified by pelleting them through a sucrose cushion (20000 rpm,
90 min, 4◦C, SW 32 Ti) and the pellet resuspended in virus stock buffer overnight at 4◦C.
After solubilising the pellet, aliquots were stored at -80◦C.
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Virus stock buffer Virus stock buffer with 15 % sucrose
50 mM Tris/HCl 75 g D(+) saccharose
12 mM KCl add 500 ml virus stock buffer
5 mM EDTA
adjust pH 7.8 by HCl
2.2.7.4 Determination of MCMV titre by standard plaque assay
The viral titre was determined by applying of a dilution series onto MEF cells and counting
of plaques 4 days pi. Therefore MEF cells were distributed on 48 well plates 24 h ahead
the assay. The virus samples were serially diluted (10−1 to 10−6) in DMEM on 48 well
plates and 200 µl of each dilution were transferred onto the plates with MEFs. After 1 h
incubation the media were removed and 500 µl of methylcellulose-media were added to
each well. Numbers of plaques were determined at 4 days pi and viral titre calculated from
plaques quantity and dilution factor [71].
Virus titre (PFU/ml) = counted plaques · dilution factor
volume of virus dilution
Methylcellulose-media
3.75 g Carboxymethyl-cellulose (400-800 cps)
388 ml H2O, autoclaved
25 ml FBS
50 ml 10x MEM
5 ml Q
2.5 ml NEAA
5 ml P/S
24.7 ml NaHCO3
2.2.7.5 Determination of MCMV titre by TCID50
As the viral growth of MCMV∆M94tTA was dependent on the complementing cell line
NTM94 and this cell line did not exhibit contact inhibition, the determination of viral
titre by plaque quantification was not applicable. Therefore viral titres were defined by
tissue culture infective dose 50 (TCID50) [35]. NTM94 cell were splitted 1:12 onto a 96
well plate by 100 µl each well. After 4 h of cell growth, the virus was diluted 1:100 and
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serial diluted in media on 96 well plates in 1:10 dilution steps. From this plates 100 µl of
each well were transferred to the corresponding wells of the plate with. In doing so the
residual medium of the cells was not removed and the cells were incubated for 4 days and
stained with crystal violet. Plaques positive wells were counted and viral titre calculated
according to Reed and Mu¨nch method [72].
10x Crystal violet
10 % formaldehyde in DPBS
1 % (w/v) crystal violet
2.2.7.6 Growth kinetics of MCMV
Each virus was analysed in duplicates and if necessary in absence and presence of Dox in
viral growth analysis. MEF cells were splitted 1:5 on 2 of 12 well plates and the cell number
of three wells was determined after 24 h. Cells were infected with MOI of 0.1 by addition
of diluted virus stock in 1 ml final volume of standard media in absence of Dox. After
incubation for 1 h, the supernatants of 4 wells, 2 for each duplicate were harvested and all
wells were washed 3 times with DPBS, before addition of fresh medium to one plate and
fresh medium including Dox to the second plate. Supernatants were harvested every day
up to 5 days pi. They were stored at -80◦C and the number of released infectious particles
for each time point were determined by standard plaques assay.
2.2.8 Packaging assay
The packaging assay was based on the different genome forms occurring during the MCMV
replication (section 3.12), primarily concatemers and cleaved genomes. These forms were
distinguished by different fragments recognised by a probe in a Southern blot analysis.
The generation of the probe for the Southern blot analysis was described in section 2.2.3.1.
The DNA was isolated from infected cells (section 2.2.2.6) harvested 48 hpi.
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2.2.8.1 Southern blot analysis
The probe was generated by PCR using the primers Apa2-for and Apa2-rev (section 2.1.8)
on pSM3fr-FRT as template. The PCR product was purified by GFX PCR DNA and Gel
Band Purification Kit (section 2.2.3.2). M210B4 cells were infected with MOI 0.1 to 0.5
and total cellular DNA was isolated 48 hpi. From these 1 µg DNA of infected cells was
digested by 40 units of ApaLI in a final volume of 40 µl overnight at 37◦C. The DNA was
then applied to agarose gel electrophoresis at 80 V for 24 h. The gel size was reduced to
minimal size for detection of required bands and size marker was documented by photogra-
phy of the gel next to a ruler. To mobilise the DNA in the gel, it was incubated in 250 mM
HCl twice for 10 min and subsequently for 45 min in denaturation buffer. Afterwards the
gel was incubated for 30 min, followed by additional 10 min, in neutralisation buffer.
The DNA was then transferred by capillary force to a membrane (Amersham Hybond
TM
-
N+, GE Healthcare). For this, blotting paper (Macherey-Nagel) in gel width was placed in
an agarose gel electrophoresis chamber with both ends dunked in 20x SSC buffer. The gel
was placed onto the paper and the membrane in gel size on top of the gel. The capillary
force was established by 2 gel size blotting papers soaked in 20x SSC and 2 additional dry
ones, followed by a tower of tissue papers. This was fixed by weight and balanced. Blotting
was performed overnight.
The papers were removed the next day and the DNA on the membrane was cross-linked
by 0.125 Joule UV-light. The gel was investigated for remaining DNA by UV illumination.
The membrane was then transferred into 20 ml hybridisation buffer (DIG Easy Hyb Gran-
ules from Roche) and incubated at 60◦C for 4-5 h in a hybridisation oven. The probe was
boiled for 10 min at 95◦C to separate double strand DNA, before added to the hybridisa-
tion buffer. The incubation was continued at 60◦C overnight.
The next day the membrane was washed twice for 5 min with washing buffer I at RT and
twice for 15 min with washing buffer II at 60◦C. DIG labeled probes were detected using
the DIG Luminescent Detection Kit from Roche according to manufacturers instructions
and exposure to chemiluminescence film.
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Denaturation buffer Neutralisation buffer 20x SSC
1.5 M NaCl 1 M Tris 3 M NaCl
0.5 M NaOH 1.5 M NaCl 0.3 M sodium citrate
pH 7.4
Washing buffer I Washing buffer II
2 % SSC 0.5 % SSC
1 % SDS 1 % SDS
2.2.8.2 Quantification of Southern blot analysis
For quantification of Southern blots, the signal was illuminated by fresh CSPD from the
DIG Luminescent Detection Kit and chemiluminescence signal was quantitative detected
using a typhoon scanner. The resulting image was evaluated by Image Quant software and
the values compared to each other.
2.2.9 Protein analysis
2.2.9.1 Protein extraction from eukaryotic cells
NIH3T3 cells were infected with MOI 0.1 to 0.5 and additives (Dox, PAA) were added 1 hpi
if needed. Cells were harvested 24 hpi by scraping cells in DPBS on ice and collecting by
centrifugation (6,800 g, 3 min, 4◦C). The pellet was washed by resuspending in 1 ml DPBS
and centrifugation (6,800 g, 3 min, 4◦C). Cell pellets from 6 cm cell culture dish were
resupended in 150 µl total lysis buffer and cell pellets form 10 cm dishes in 250 µl total
lysis buffer. 1 µl benzonase for each 50 µl total lysis buffer was added and incubated on
ice for 90 min, before snap frozen in liquid nitrogen and transferred to -80◦C storage.
Total lysis buffer
62.5 mM Tris/HCl pH 6.8
2 % (v/v) SDS
10 % (v/v) glycerol
6 M urea
5 % (v/v) β-mercaptoethanol
0.01 % (w/v) bromphenolblue
0.01 % (w/v) phenolred
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2.2.9.2 SDS-PAGE
SDS-PAGE were prepared according to following table. Samples were incubated at 95◦C
Stacking gel (4 %) Resolving gel (12 %)
Rotiphorese R© Gel 30 4 ml 2.5 ml
Gel buffer 2.5 ml 3.75 ml
H2O 3.4 ml 9.75 ml
10 % APS 100 µl 100 µl
TEMED 3.3 µl 20 µl
for 10 min prior to loading on the gel. Proteins were separated by 160 V for 1-2 h in
Laemmli buffer.
Stacking gel buffer Resolving gel buffer 10x Laemmli
0.5 M Tris 1.5 M Tris 250 mM Tris
0.4 % (w/v) SDS 0.4 % (w/v) SDS 2 M glycine
pH 6.8 pH 8.8 1 % (w/v) SDS
2.2.9.3 Western Blot analysis
For western blot analysis the proteins separated by SDS-PAGE were transferred onto a
PVDF membrane (Amersham Hybond
TM
-P, GE Healthcare) by semi dry blotting using
Trans-Blot
TM
SD Semi-Dry Eletrophoretic Transfer cell from Bio-Rad according to manu-
facturers instructions.
The membrane was blocked with 5 % (w/v) skimmed milk powder in TBST overnight at
4◦C. Subsequently the membrane was washed 3 times with water and twice with TBST,
before incubated with the first antibody in 5 ml TBST for 2 h at 4◦C. The membrane was
then washed with TBST for 10 min to 2 h depending on the first antibody. Incubation
with the second antibody was performed in 5 ml TBST for 1 h at RT and membrane was
washed with TBST again for 10 min to 2 h.
Signals were detected by using ECL Plus (GE Healthcare) according to the manual and
exposure to chemiluminescence films.
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First antibody (dilution) Second antibody (dilution) Washing time
α-pp89 (1:3000) α-mouse (1:8000) 2 h
α-M50 (1:3000) α-rabbit (1:8000) 30 min
α-M94 (1:2500) α-rabbit (1:8000) 2 h
α-HA-Pox (1:1500) – 10 min
Blotting buffer TBST
24 mM Tris 150 mM NaCl
192 mM glycine 10 mM Tris/HCl pH 8.0
20 % (v/v) methanol 0.05 % Tween20
Chapter 3
Results
3.1 M94 is essential in MCMV
UL94, the homologue of M94 in HCMV was proven to be essential [25]. This indicated
that M94 will also be essential for virus growth in cell culture. This property was also
crucial in this study. Here, the analysis of mutants in the viral context was based on their
capacity to rescue viral productivity. Only mutations affecting an essential gene and hence
affecting the MCMV life cycle could be detected. Therefore the essentiality of M94 was
inspected.
Figure 3.1 shows for verification of the essentiality the growth analysis of wt MCMV-FRT,
an M94 deletion mutant, and two M94 ectopic revertants. A schematic representation of
the mutant genomes is included. The rescue strategy was based on cis-complementation.
In this case the phenotype of no viral growth of the deletion mutant which requires trans-
complementation of the protein is compensated by introduction of the deleted gene in cis,
so on the identical DNA, but at a different position in the genome to exclude polar effects.
The deleted gene is complemented by the expression of the ectopically inserted gene. By
restoration of the wt phenotype the gene is identified as exclusive factor for the deletion
phenotype.
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Figure 3.1: Schematic representation of the mutant genomes and their growth kinetics of wt (MCMV-FRT, green), M94
deletion mutant (MCMV∆M94tTA, violet), rescue under control of endogenous M94 promoter (MCMV∆M94-EPM94, gold)
and rescue under control of the CMV promoter (MCMV∆M94-EHAM94, yellow), the latter with HA-tagged M94.
Growth analysis on MEF was initiated at MOI of 0.1 with inoculi generated from trans-
fected BACs (section 2.2.7.1) for all viruses and the titre drop on day 1 indicated strin-
gent washing. Wild type virus MCMV-FRT contained the complete MCMV genome and
demonstrated standard growth kinetics up to 106 PFU/ml at 5 dpi. The deletion virus
MCMV∆M94tTA (section 2.1.9) was deleted in M94 replaced by tTA and in m157 replaced
by a floxed OVA-cassette and produced on a complementing cell line. After infection with
the same MOI no production of any viral progeny was detected. This phenotype was
rescued by Flp-FRT mediated ectopic insertion of M94 either under control of endoge-
nous M94 promoter (MCMV∆M94-EPM94) or under control of HCMV immediate early
promoter enhancer, further called CMV promoter (MCMV∆M94-EHAM94) into the M94
deleted MCMV genome. Both rescues showed titres comparable to wild type. Hence, the
essentiality of M94 was proven for MCMV.
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The analysis of MCMV∆M94-EHAM94 also demonstrated that the M94-ORF itself is suf-
ficient for the rescue of the null phenotype of the deletion and there is no polar effect of the
deletion and the expression under control of a different promoter was functional. Finally
the analysis showed the fitness of the HA-tagged protein in MCMV∆M94-EHAM94. The
virus titres were comparable to wt, demonstrating that the HA-tag has no influence on
viral fitness.
3.2 Transposon mutagenesis
For the analysis of the essential M94 function, the genetic approach of random mutagenesis
was chosen. As described in section 1.2.4 the random mutagenesis was achieved by a
transposon mutagenesis. In order to explain the individual steps of the mutagenesis and
the differences between the modified mutagenesis and the original one, the transposon
mutagenesis will now be detailed, followed by a report on the actual experiment.
The GPS R©-LS Linker scanning system was used for the in vitro transposition reaction. To
this end the donor vector and the target vector are combined with the transposase enzyme
(Fig. 3.2) in a transposition reaction. The applied transposase TnsABC∗ is a mutated
Tn7 bacterial enzyme [88]. The original form consists of 4 subunits and insertion of the
transposon either at a specific site or randomly depends on the subunit composition [21].
The mutated form lacks the subunit determining the integration manner and thus the
sequence dependency is decreased. Besides, the target immunity of Tn7 prevents a second
insertion [89] of a transposon into a Tn7 containing DNA up 100 kbp in vitro and 1 Mbp
in vivo [21].
The transposon utilised in this study, called transprimer, consists of the Tn7-ends with
PmeI-restriction sites and a chloramphenicol-resistance for selection [6]. Due to its origin
of replication, the donor vector pGPS4 containing the transprimer can only be propagated
in PIR1 bacteria as these bacteria express the replication protein Π, which is required for
replication of plasmids containing the R6Kγ origin of replication [57]. pGPS4 is therefore
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Figure 3.2: Overview of GPSR©-LS Linker Scanning system [7]. The transprimer of the donor vector is randomly inserted
into the target vector by the transposase (TnsABC*). The majority of the transprimer is removed by PmeI restriction and
religation, resulting in a 15 bp insertion including a PmeI restriction site.
lost in further reaction steps carried out in DH10B.
The random insertion by the transposase does not facilitate generation of compatible ends
in the target vector. After the donor change, the transprimer is therefore connected to
the plasmid at overhangs of the DNA backbone and the remaining gaps are filled during
plasmid replication in vivo. This results in the repetition of 5 bp at both ends of the
transprimer (Fig. 3.3), forming part of the mutation.
By excision of the transprimer by PmeI digest one PmeI restriction site of 8 bp resides
along with 2 bp remaining from the transprimer. Subsequent to the religation of the vector,
these 10 bp along with the duplicated 5 bp result in the insertion of 15 bp. Depending on
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Figure 3.3: Strand transfer reaction in the transposition [7]. The restriction of the donor vector by the transposase enzyme
(slight arrows) produces 3’ overhangs, whereas the target vector is generated with 5’ overhangs. The random insertion
produces incompatible ends and therefore the resulting construct is repaired in vivo, in this process 5 bp are duplicated. The
PmeI digest removes the transprimer and generates the insertion.
the frame of the insertion this produces in 2
3
of all mutations an insertion of 5 amino acids
(aa) or in 1
3
of the cases a stop codon (Fig. 3.4).
3.3 Cloning of M94
A target vector in the GPS R©-LS Linker Scanning system has to meet several requirements.
First a PmeI restriction site is not allowed in the target construct. Second, the vector
must be sensitive to chloramphenicol, and finally the vector must be able to replicate in
bacterial strains other than PIR1. Also, the target vector should not contain Tn7 ends
to prevent target immunity. The sequence size ratio between the gene of interest and
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Figure 3.4: Generation of 5 aa insertion. The total insertion of 15 bp is illustrated with the duplicated base pairs shown in
black, the PmeI restriction site in red, and the one base pair remaining from the transprimer in blue. The insertion can take
place into the three frames and in both orientations. This results in 6 options with 2 of them representing stop codons and
the other 4 resulting in 5 aa insertions [7].
the vector backbone is relevant as the transprimer insertions occur both into the gene of
interest as well as into the backbone. Therefore M94 was subcloned into Litmus28.
The vector pOriR6K-ie-HAM94 (section 2.1.7) was utilised for one rescue in the previous
growth analysis (section 3.1). It contains the M94-ORF with an N-terminal HA-tag. Using
KpnI and SalI, HA-M94 was excised from pOriR6K-ie-HAM94 and ligated into Litmus28
opened with KpnI and XhoI. The resulting vector, Litmus28-HAM94, was analysed by
restriction using several enzymes (Fig. 3.5). This vector Litmus28-HAM94 was utilised in
the transposon mutagenesis.
3.4 Transposon mutagenesis of M94
In order to separate insertions into M94 from insertions into the vector backbone, the
transposon mutagenesis was modified. Figure 3.6 illustrates the modified mutagenesis.
The transposition (A) reaction was performed according to the GPS R©-LS Linker Scanning
manual.
The transposition reactions are recorded in table 4.1 and conditions were selected according
to the manual [7]. The negative control, control 1, contained no transposase enzyme,
whereas control 2 served to spot influences of HA-M94 on the reaction, as it contained
Litmus28 vector solely. Subsequently electrocompetent E. coli XL1 blue bacteria from
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Figure 3.5: Restriction analysis of Litmus28-HAM94 by HincII (H), DraI (D), ApaLI (A), and BglII (B) digest. The HincII
digest resulted in a 3,077 bp fragment and two additional fragments with 385 bp and 363 bp, represented by a thick band.
The restriction using DraI produced two bands with 3,075 bp and 750 bp. Also the digest by ApaLI and BglII resulted in
two bands respectively. These were 2,088 bp and 1,737 bp for ApaLI and 3,370 bp and 446 bp for BglII in size.
Table 3.1: The transposition reaction was composed according to the manual with additional controls for reaction efficiency [7].
control 1 control 2 reaction
Litmus28 (20 ng/µL) 4 µL 4 µL –
Litmus28-HAM94 (20 ng/µL) – – 4 µL
10xGPS buffer 2 µL 2 µL 2 µL
pGPS4 (20 ng/µL) 1 µL 1 µL 1 µL
H2O 12 µL 11 µL 11 µL
Transposase – 1 µL 1 µL
Stratagene were transformed with 1
10
of controls and reaction. Transformations were plated
on ampicillin-chloramphenicol-agar plates. The result showed no colonies for control 1 and
comparable colony numbers for control 2 and the reaction.
The size of this library pool (Fig. 3.6B) was calculated as 5.99×105 clones from the trial
plating. For first analysis, 20 clones out of this pool were analysed for their transprimer
insertion (Fig. 3.7).
M94 including the transprimer has a size of 2,488 bp, leaving a 2,723 bp fragment of the
vector. These two bands were present in lane 4, 10, 13, 19 and 20. The additional band
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Figure 3.6: Overview of the modified transposon mutagenesis. The transprimer (blue) was excised from the donor vector
pGPS4 and randomly inserted into the target vector Litmus28-HAM94, containing HA-tagged M94 (orange). Out of the
mutant pool with random transprimer insertions (B), mutants containing insertions in HA-M94 were subcloned into the
expression vector pOriR6K-ie. Restriction using PmeI and religation of the vector resulted in a 15 bp insertion.
in lane 13 and 19 referred to vector backbone including transposon from a second clone
isolated in the same sample. As HA-M94 comprises about a quarter of the total target
plasmid sequence, the same proportion of the isolated clones was expected to acquire a
transprimer insertion in HA-M94, disregarding non viable mutants containing transprimer
insertions in the origin of replication or the ampicillin resistance. With the 5 clones positive
for transprimer insertion in M94, this expectation was met, indicating that the mutagenesis
was indeed random.
To reject mutations outside the HA-M94 sequence, the M94-ORF containing the transprimer
was subcloned into the expression vector pOriR6K-ie. To do so, a portion of the library
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Figure 3.7: Restriction analysis of the transprimer insertions into Litmus28-HAM94. The DNA of 20 mutants was isolated
and digested using Acc65I and NsiI, numbered 1 to 20 in the figure. Litmus28 was also digested as control (c). By this
restriction the HA-M94 was excised from the vector, with a size of 1,102 bp, leaving a vector fragment of 4,101 bp. HA-M94
including the transprimer was 2,488 bp in size, leaving a 2,723 bp vector fragment. These desired two bands were present in
the mutants no. 4, 10, 13, 19 and 20.
was plated. This portion contained enough clones to statistically allow one mutation per
base pair of HA-M94 for at least 150 times (59,900 clones). All colonies were harvested, the
DNA of the pool was isolated, and restricted using Acc65I and NsiI, the same restriction
as for the analysis (Fig. 3.7). By this procedure the DNA fragment HA-M94 containing
the transprimer was excised from the vector, isolated and subsequently ligated into the
Acc65I/NsiI opened expression vector pOriR6K-ie. At this stage the library contained
1.2×107 clones. As the library size did not decrease compared to the earlier step, the
diversity of the library was kept during the subcloning. In order to verify the enrichment
of insertions in M94 in the library pool, 20 clones were analysed for their transprimer in-
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sertion in HA-M94 (Fig. 3.8).
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Figure 3.8: Restriction analysis of the transprimer insertions into HA-M94. DNA of 20 mutants, numbered 1 to 20 in the
figure, was isolated and digested using Acc65I and NsiI. The pOriR6K-ie vector was digested as control (c), as HA-M94
containing the transprimer was subcloned into this vector. The digest resulted in two fragments of 2,488 bp and 2,390 bp,
corresponding to HA-M94 including the transprimer and vector fragment, respectively. Both bands were present in each of
the 20 tested mutants.
As in the previous analysis the 2,448 bp band indicated HA-M94 including the transprimer
insertion, resulting in a vector fragment of 2,390 bp. Both bands were indeed detected in
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each of the 20 analysed clones (Fig. 3.8). This demonstrated the successful elimination
of undesirable transprimer insertions in the vector backbone by subcloning of the library
pool. Thus the quantity of transprimer insertions in HA-M94 in the library pool increased
from 4 out of 20 in the first analysis to 20 out of 20 in the second analysis.
In order to remove the transprimer from the vector, a library portion was plated (1,200,000
clones) as in the previous step and DNA was isolated from collected colonies. The diges-
tion of this DNA pool using PmeI enabled the isolation of the remaining vector fragment
by extraction from agarose gel and thereby the removal of the transprimer. By religation
of the isolated vector, the final mutation of a 15 bp insertion was generated. The final
library of M94 mutants contained 3.2×104 clones, which statistically corresponded to 25
mutations per base pair of the 1,120 bp of the subcloned fragment without the transprimer.
Therefore the library was expected to cover the M94-ORF, given that no hot spots were
present.
About 100 of the clones were analysed for their loss of chloramphenicol resistance mediated
by the transprimer through parallel growth analysis on LB agar plates containing either
chloramphenicol and zeocin or exclusively zeocin. All of them were chloramphenicol sen-
sitive. Additionally 20 mutants were analysed to position the 15 bp insertion (Fig. 3.9).
As the insertion maintained a PmeI restriction site, the position could be identified by
digestion using PmeI and NdeI, the latter present as unique restriction site in the vector.
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Figure 3.9: Restriction analysis for the position of the mutation in HA-M94. Again the DNA of 20 mutants was isolated,
numbered 1 to 20 in the figure. The digest by NdeI and PmeI revealed the position of the mutation, due to the PmeI
restriction site in the mutation and the fixed NdeI restriction site in the vector. The size of the resulting fragments depended
on the PmeI restriction site position compared to the NdeI restriction site. The fragment sizes were different in most mutants,
demonstrating different mutations for each.
The PmeI-NdeI-digest resulted in two fragments corresponding in size to the position of
the mutation. Since the position of the NdeI restriction site was defined in the vector and
the PmeI restriction site was dependent on the location of the 15 bp insertion, the distance
to the NdeI restriction site varied. Accordingly, most fragments differed in size (Fig. 3.9),
reflecting the different positions of the insertions. The screen revealed no preferred insertion
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sites for the transprimer in HA-M94 suggesting a library with covering mutations.
Based on the above data, 37 clones were sequenced. The sequences revealed 23 insertion
mutants and 11 stops mutants, whereas 3 mutations were outside the M94-ORF. This
represented 63 % insertion mutants and 30 % stop mutants, reflecting the ratio 3:1 of
insertion mutants to stop mutants as expected by the transposon mutagenesis (Fig. 3.4).
The mutants also showed a random distribution over the M94-ORF, with only two stop
mutation at the same position. No insertion mutants occurred at the same position, but 3
could be found in a range within 5 aa.
3.5 Analysis of the M94 library
As the library passed the quality control, an expanded analysis was performed to cover the
whole M94-ORF. Therefore a larger pool was plated and single colonies were picked. The
DNA from these colonies was isolated and sequenced. For sequencing two primers were
used to cover the M94-ORF at least on one strand.
In total 613 mutants have been sequenced. From these 494 had a correct mutation in M94,
namely one 15 bp insertion in the M94-ORF. About 10 % of the mutations were incorrect
due to the transposon mutagenesis as declared by the manufacturer [7]. The remaining
10 % incorrect mutations consisted of 5 % mutations outside of the M94-ORF either in
the 85 bp up- and downstream to the ORF that were kept during subcloning or in the
HA-tag and further 5 % of the mutants where the sequence revealed a mixed clone. The
latter ones could have been singularised and sequenced again, but as the library displayed
sufficient coverage, this was not necessary.
From the 494 correct mutants, 399 mutations were unique, implying mutations in the
same base pair were counted as one mutation. This clearly demonstrated that the library
contained almost no preferred insertion sites for the transprimer, as the unique mutations
occurred in 80 % of the correct mutations. Among the mutations which were found more
than once, appeared 58 % twice, 22 % three times and 20 % four times or more.
The mutants were named corresponding to the number of the last amino acid before the
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insertion, with i for insertion and s for stop mutant. From the identified mutants, 14 stop
mutants equally distributed over the M94-ORF were selected to analyse dispensable parts
of M94. In addition, 60 insertion mutants distributed equally were selected for the detailed
analysis. The preferential distance between the insertions was 5 aa. Since the isolated
samples did not reflect the total library, a few insertions were spaced up to 12 aa apart.
Figure 3.10 shows the M94-ORF depicted as line and in A the insertions mutants at their
positions in M94 are displayed, whereas the stop mutants are illustrated in B.
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Figure 3.10: Selected insertion mutants (A) and stop mutants (B) on the HA-M94 sequence. The 60 insertion mutants and
14 stop mutants picked for analysis are indicated in the sequence of HA-M94, depicted as line. They are named with i for
insertion and s for stop and the number of the aa in front of the mutation.
The influence of the mutation on the function of M94 was investigated in the viral context.
So the role of M94 in the MCMV life cycle was analysed and also essential regions in M94
could be defined.
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3.6 Analysis of M94 mutants in the viral context
To analyse the mutants in the viral context, mutants were individually inserted into the
MCMV genome by means of the Flp-FRT system using BAC technology. The Flp recom-
binase was expressed from the plasmid pCP20 [15], which contains a temperature sensitive
replicon. Therefore, it is unable to replicate at temperature above 37◦C. The Flp recombi-
nase recognises the FRT sites and mediates site specific recombination between the MCMV
BAC containing a FRT site and the rescue plasmid harbouring the mutant M94 gene also
including a FRT site (section 2.2.5.2).
Since the wt ORF succesfully complemented the deletion of endogenous M94 after inser-
tion at an ectopic position (Fig. 3.1), the BAC deleted in its endogenous M94 can also
be used to test the complementation of M94 function by the mutant upon insertion. On
account of this the mutant could or could not accomplish the M94 function resulting in
virus rescue. Therefore the analysis was named loss-of-function screen and a scheme of the
analysis in presented in figure 3.11. The mutants are individually inserted into the deletion
BAC via the Flp-FRT system. The plasmid pCP20 expressing the Flp recombinase was
then lost due to the temperature shift from 30◦C to 43◦C. Subsequently DNA from colonies
was isolated and the restriction analysis revealed, whether the mutant was inserted once
or repeatedly into the BAC. The latter mutants were rejected from the analysis and only
single insertions were proceeded further.
A representative example for restriction analysis is shown in figure 3.12 using NsiI. The
successful insertion of plasmids carrying the mutant gene was indicated by the loss of the
1,930 bp band of the control as well as the appearance of an additional band of 4,771 bp
in the mutant BACs. Double insertions were identified by a band 3,510 bp in size. Conse-
quently double insertions, in this gel example the lanes 3, 4 and 7, were identified. In total
7 rearranged BACs and 58 double insertions occured in this analysis of about 342 samples.
As shown in figure 3.11, identified single insertions were then selected and singularised.
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Figure 3.11: Loss-of-function screen. This
figure represents a workflow of the analysis of
the M94 mutants in the viral context to de-
termine essential regions of the protein. The
mutants were individually inserted into the
MCMV BAC deleted in M94 via the Flp-FRT
system. Constructs were checked for double
insertions and clones with single insertions
were selected. New DNA was isolated for re-
striction analysis and virus reconstitution on
murine fibroblasts.
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Figure 3.12: Restriction analysis for identification of double insertion. The mutant BACs (no. 1 to 9) were restricted by NsiI
and the parental BAC with M94 deletion was added as control (c). A schematic representation of the restriction is shown
on the right and vanishing and upcoming bands are marked by thick lines. The insertion of the M94 mutants was detected
by the loss of the 1,930 bp band in the control and a new band at 4,771 bp in the mutant BACs. Double insertion were
identified by an additional band at 3,510 bp.
Fresh DNA was isolated from single colonies and analysed by restriction analysis using 3
different enzymes, to ensure correct BACs with single insertion.
A representative example for this restriction analysis is shown in figure 3.13. The digest
shown in A is equal to the digest presented in figure 3.12, with the 1,930 bp band present
in the control, but lost in the mutant BAC. The mutant BACs show the additional band
of 4,771 bp.
The digest by HindIII showed only a faint difference in the restriction pattern of the control
and the mutant BAC, which could not be identified in the gel. Nevertheless the restriction
was useful in detecting rearrangements in the BAC itself, as seen in BAC mutant no. 10.
The PsiI digest finally showed two additional bands in the mutant BACs, with a size of
1,035 bp and 6,991 bp. Out of this presented BAC mutants, all were assessed correct,
except no. 5 due to the failed PsiI digest, which was repeated (data not shown) and no.
10 as unidentified bands were detected in the HindIII digest for this the BAC was rejected,
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appearing in 15 mutants of about 228 analysed mutants. The correct BACs were used for
subsequent analysis.
Finally BACs passing the restriction analysis were reconstituted on murine embryonic
fibroblasts, along with mock control without DNA, a negative control containing a replica-
tion deficient deletion BAC, and a positive control comprising wt DNA. The reconstitution
of the mutant BACs resulted in viral progeny, indicated by total cell lysis in a time frame
comparable to the wild type lysis. No detectable cell lysis after six weeks was evaluated as
no viral reconstitution.
The loss-of-function screen was performed for all mutants with two independent clones to
ensure the observed phenotype. Conflicting results, in total 8 in all analysed mutants,
were dissolved by isolation and reconstitution of two additional mutants. Viral progeny
indicated the successful complementation of the missing endogenous M94 by the mutant,
whereas no viral progeny demonstrated the incapability of the mutant protein of fulfilling
the native M94 function.
The results of the loss-of-function screen are summarised in figure 3.14. In case the mutant
successfully provided the wt M94 function, viral progeny was produced. This indicated
that no essential function of the protein was inhibited by the mutation. If the mutant
failed to substitute wt M94, there was no viral progeny. This suggested that a sequence
region corresponding to an essential function of M94 was targeted by the mutation. Thus,
regions in M94 corresponding to essential functions could be successfully defined in this
loss-of-function screen.
As 39 of the 60 tested insertions mutants produced viable virus, only 21 insertion mutants
failed to support viral progeny. So 65 % of the insertion mutants demonstrated no effect on
the M94 function, suggesting a relative insensitivity of M94 to insertions. This is reflected
by the bioinformatic analysis of M94 indicating a predicted α-helix in the conserved C-
terminus and only a few other small secondary structures. Apparently secondary structures
were infrequently not destroyed by insertion mutations and also a potential linker sequence
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Figure 3.13: Restriction analysis of the BAC
mutants in the loss-of-function screen. The
mutant BACs, in the gels numbered 1 to 12
and in the scheme labelled as mut were re-
stricted using NsiI, HindIII, and PsiI with
the M94 deletion BAC as control (c). The
schematic gels indicate the differences in re-
striction patterns by thicker lines.
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Figure 3.14: Result of the loss-of-
function screen. The amino acid se-
quence of M94 is shown in single let-
ter code and aa position are indicated
in A, B, and D. Insertion mutants are
depicted as arrowheads, stop mutants as
diamonds, and both at their position on
the aa sequence. Viable constructs are
illustrated in green, whereas non viable
mutants appear black. In C the similar-
ity blot of 35 homologous sequences of
Herpesviridae are presented, whereas in
D the bioinformatic analysis of the pro-
tein with predicted α-helices, β-sheets,
and an underlined linker are shown.
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(121-170 aa) connecting two protein domains was not influenced by insertions. At the same
time every stop mutant except the last one resulted in no viral progeny. This last stop
mutant s342 deleted only the last three aa of M94, which were not included in the conserved
part of the C-terminus, demonstrating that indeed the C-terminus is the only conserved
part of the protein. Therefore, the C-terminal part of M94 is not dispensable.
3.7 Identification of inhibitory mutants
Next to the identification of essential regions in M94, further aim of this study was the
indentification of potential DN mutants of this protein. To do so, the mutants were analysed
in the so called inhibitory screen, which utilised a different genome context.
The assay was similar to the assay illustrated in Fig. 3.11, except that the mutant M94
genes were introduced into the wt MCMV instead of the M94 deletion BAC. So the mutants
were inserted ectopically in addition to the endogenous M94 (Fig. 3.15). A DN mutant
would abolish the viral production by inhibition of an essential M94 function. Therefore
the mutant had to interfere with the activity of the endogenous M94, which allowed the
identification of a potential DN mutant as defined in section 1.2.5.
By definition a DN mutant can not complement the wt M94 function in the M94 deletion
background and can not produce viral progeny in the loss-of-function screen. Therefore, all
mutants having failed in virus reconstitution in the loss-of-function screen were also tested
in the inhibitory screen. Additionally 8 stop mutants in the C-terminus were analysed,
as the C-terminus appeared to be very sensitive to changes in the loss-of-function screen.
Again two independent clones for each mutant were analysed to verify the observed phe-
notype.
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Figure 3.15: Inhibitory screen. This figure il-
lustrates the workflow of the analysis of the
M94 mutants in the viral context to iden-
tify inhibitory mutants. The screen differed
to the loss-of-function screen (3.11) only in
the introduction of the mutants into the wt
MCMV-BAC instead of the M94 deletion
BAC. So in this inhibitory screen, the mu-
tants were inserted in the presence of the en-
dogenous M94.
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Figure 3.16: Result of the inhibitory screen. The amino acid sequence of M94 in single letter code and the aa positions
are presented. Stop mutants are indicated by diamonds, insertions mutants by arrowheads, both at their position in the aa
sequence. Viable mutants are illustrated in green and non viable in black.
Figure 3.16 illustrates the result of the inhibitory screen. 42 mutants analysed in this
screen and 40 of them produced viral progeny like wild type and none of the stop mu-
tants demonstrated inhibitory function. But two insertion mutants at the very N-terminus
showed no viral reconstitution, the insertion mutants at the aa positions 7 and 13, named
M94i7 and M94i13. Althogether, two inhibitory mutants were identified by this assay.
The analysis by the inhibitory screen only demonstrated an inhibition of the reconstitution
of virus. To exclude toxicity of the mutants inhibiting viral reconstitution, these inhibitory
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mutants were further analysed. In the following assay also infectious virus is analysed,
which needs to pass through the complete viral life cycle.
3.8 Verification of the dominant negative mutants
To analyse the phenotype introduced by the inhibitory mutants, they have to be expressed
in the viral context. This requires either delivery of the mutant expression cassette in
trans or construction of a recombinant virus which expresses the inhibitory mutants in a
conditional fashion. In the latter case the transcription unit encoding the mutant needs to
be off during virus reconstitution and must be turned on when analysis of the phenotype
is needed. This enables the parallel analysis of the phenotype produced by the expression
of the DN and the phenotype without its expression in the same construct.
Figure 3.17: Conditional expression cassette (adapted from [77]). The constitutively expressed tet-repressor (tetR) binds to
the tet-operator (tetO2) in the promoter region of the M94 mutant, thereby preventing transcription. By addition of Dox
the tetR binding to the operator is inhibited in binding and the mutant can be expressed.
The Dox inducible expression cassette (Fig. 3.17) which was described in Rupp et al. [77]
enabled the study of mutants of dominant negative MCMV proteins. The cassette contains
a tet-repressor (tetR) gene under control of the CMV promoter. The repressor protein
(TetR) is therefore constitutively expressed and binds to the tet-operator (tetO2) in the
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promoter region of the mutant gene, which is expressed under control of either the SVT
promoter or the CMV promoter. This TetR binding inhibits the expression of the mutant
protein (OFF). Only by addition of Dox, which binds to the TetR and prevents its binding
to the tetO2, expression of the mutant is induced (ON).
The mutants to be analysed were cloned by PCR from the library constructs into the vectors
containing the different cassettes with either the SVT or the CMV promoter by MluI and
PvuII digest. These vectors were restricted by AscI and HpaI and dephosphorylated prior
ligation with the digested PCR fragments, resulting in 4 constructs, verified by sequencing.
These constructs were analysed for the conditional expression of the mutants.
The mutant cassettes were introduced into the BACs via the Flp-FRT system as described
in Fig. 3.11. They also were analysed by restriction analysis and proper clones were selected
for reconstitution. For the analysis in the viral context the mutants were introduced into
two different BACs. The first pSM3fr-FRT, contains the entire MCMV genome and an
FRT site between the genes m16 and m17. The second pSM3fr-FRT-∆1-16, lacks the genes
m01 to m16 and also contains an FRT site. The genes m01 to m16 are not essential for
viral growth in cell culture [18]. Integration of the cassette into pSM3fr-FRT produces an
overlength genome, which is avoided when using pSM3fr-FRT-∆1-16 as backbone. The
overlength reduces the packaging efficiency of the virus and consequently inhibits growth.
By passaging the virus several times, the BAC-cassette of the cloned MCMV genome is
lost and the slight growth deficiency is resolved [91]. As there are already genes deleted in
pSM3fr-FRT-∆1-16 no overlength is produced and passaging is not necessary. Therefore
the pSM3fr-FRT-∆1-16 MCMV genome can be used directly in cell culture experiments
without extensive passaging the recombinants before analysis.
In total, 8 different constructs for the analysis of the mutants in differend genome backbones
and under control of different promoters were produced as recorded in table 3.2. The
resulting viruses were named accordingly by replacing pSM3fr by MCMV. Meanwhile ”R”
in RM94i7/13 referres to the ectopic insertion of the conditional cassette containing the
mutant, whereas in constructs named EHAM94 the ”E” implies ectopic insertion of the
pOriR6K vector, so M94 under control of the CMV promoter with constitutive expression
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(Fig. 3.1).
Table 3.2: Conditional expression constructs. The pSM3fr-FRT BAC contains the whole MCMV genome, whereas pSM3fr-
FRT-∆1-16 BAC is deleted in the genes m01 to m16. The pOriR6K vectors including the inhibitory mutants M94i7 and
M94i13 in the conditional expression cassette either with the CMV (pO6CMV) or the SVT (pO6SVT) promoter, were inserted
into the BACs. The resulting constructs are named as shown and the resulting viruses accordingly.
parental BAC pOriR6K vector resulting construct resulting virus
pSM3fr-FRT pO6CMV-M94i7 pSM3frCMV-RM94i7 MCMVcmv-RM94i7
pSM3fr-FRT pO6CMV-M94i13 pSM3frCMV-RM94i13 MCMVcmv-RM94i13
pSM3fr-FRT pO6SVT-M94i7 pSM3frSVT-RM94i7 MCMVsvt-RM94i7
pSM3fr-FRT pO6SVT-M94i13 pSM3frSVT-RM94i13 MCMVsvt-RM94i13
pSM3fr-FRT-∆1-16 pO6CMV-M94i7 pSM3fr∆1-16CMV-RM94i7 MCMV∆1-16cmv-RM94i7
pSM3fr-FRT-∆1-16 pO6CMV-M94i13 pSM3fr∆1-16CMV-RM94i13 MCMV∆1-16cmv-RM94i13
pSM3fr-FRT-∆1-16 pO6SVT-M94i7 pSM3fr∆1-16SVT-RM94i7 MCMV∆1-16svt-RM94i7
pSM3fr-FRT-∆1-16 pO6SVT-M94i13 pSM3fr∆1-16SVT-RM94i13 MCMV∆1-16svt-RM94i13
The viral growth characteristic of these constructs and of the parental wild type viruses
were then analysed by multi-step growth curves in absence and presence of Dox, hence
without and with expression of the DN mutants.
The first growth kinetics are summarised in figure 3.18. The growth of the parental virus
MCMV-FRT-∆1-16 was not influenced by the Dox treatment (Fig. 3.18 A, B), as titres
remain equal by addition of Dox. In contrast all mutant viruses were inhibited in response
to Dox. The induction of mutant M94i7 inhibited the production of released viral particles
by 2 logs irrespectively whether its expression was under control of the CMV promoter
(MCMV-∆1-16cmv-RM94i7, Fig. 3.18A) or the SVT promoter (MCMV∆1-16svt-RM94i7,
Fig. 3.18B). The mutant M94i13 demonstrated an slightly increased inhibitory activity (2.5
logs) under control of the CMV promoter (MCMV∆1-16cmv-RM94i13, Fig. 3.18A) and
an even higher (3 logs) under control of the SVT promoter (MCMV∆1-16svt-RM94i13,
Fig. 3.18B). Since both mutant proteins were able to inhibit viral replication upon expres-
sion, they fulfilled one characteristics of a DN mutant and they will further on be named
DN mutants.
As M94i13 showed the stronger phenotype, a second clone of MCMV∆1-16cmv-RM94i13
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Figure 3.18: Growth kinetics of inhibitory mutants in the pSM3fr-FRT-∆1-16 background. Addition of Dox is indicated
by shaded bars. The parental virus MCMV-FRT-∆1-16, shown in white, was not inhibited by Dox treatment (A, B). The
inhibitory mutants M94i7 and M94i13 were expressed under control of either the CMV promoter (blue, A) or the SVT
promoter (red, B). The inhibitory mutant M94i13 demonstrated increased inhibition, which was confirmed by second clones
for both viruses (C, D).
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and MCMV-∆1-16svt-RM94i13 were analysed in a separate growth kinetic experiments
(Fig. 3.18 C, D) in comparison to the clones already assayed. Although the titres var-
ied through the growth kinetic, the final titres showed small differences, demonstrating a
clone-independent phenotype of inhibition by the DN mutant.
- Dox
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MCMV-FRT MCMVcmv-RM94i13
MCMVsvt-RM94i13
Figure 3.19: Growth kinetics of DN mutant M94i13 in the MCMV-FRT background. The addition of Dox is indicated by
shaded bars. The wt virus MCMV-FRT is presented in white and was not influenced by Dox treatment. The DN mutant
M94i13 under control of the CMV promoter (framed blue) did not respond to addition of Dox, whereas inhibition was detected
under control of the SVT promoter (framed red).
To verify the inhibitory activity showed by the previous growth curve, the mutant function
was also demonstrated in the wt MCMV backbone containing the complete genome, under
control of either the SVT or the CMV promoter (Fig. 3.19). Again the wt control MCMV-
FRT was not influenced by Dox in its growth characteristics.
The inhibition of the mutant M94i13 under control of the CMV promoter, MCMVcmv-
RM94i13, as detected in the pSM3fr-FRT-∆1-16 background (Fig. 3.18), was lost in the
wt context. In contrast, the inhibition upon Dox was still present under control of the
SVT promoter, MCMVsvt-RM94i13, which is believed to have a lower basal expression.
This difference is probably due to different basal expression strength of the promoters. In
other studies the CMV promoter mediated a stronger expression than the SVT promoter.
So the basal expression with the CMV promoter is higher and this resulted in an increased
evolutionary pressure to neutralise the effect, driving the loss of expression the DN mutant.
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Therefore, in MCMV wt background the DN phenotype was lost over time under control
of the CMV promoter, but remained stable with about 3 logs inhibition in the construct
containing the SVT promoter.
3.9 Protein analysis of the DN mutant
The basic principle of a DN effect is the overexpression of the mutant to inhibit the wild
type function (section 1.2.5). Therefore the protein expression of the endogenous M94 and
the HA-tagged DN mutant M94 were analysed.
3.9.1 Characterisation of anti-M94 serum
Anti-sera to M94 serum were produced by metabion (section 2.1.10). The two sera A and
B were produced in different rabbits. In order to test the reactivity of the sera, samples
from transfection and infection experiments were analysed by the sera and pre-sera for
specific reaction on pM94 (Fig. 3.20).
Infections were performed with mock, MCMV∆M94tTA, and MCMV∆1-16 in NIH3T3
cells, whereas the transfections in 293 cells contained either pOriR6K-ie or pOriR6K-
HAM94. The calculated size of pM94 is 37.7 kDa. As former studies of the UL94 ho-
mologue in HCMV [95] revealed no size variants, the predicted size was expected. Also a
blot stained against the HA-tag was utilised for verification of the protein identity.
The staining against the HA-tag revealed in one band at the predicted size of about 38 kDa.
The signal could only be detected in the transfection T2 as the wt infection contained no
HA-tagged M94 and the transfection T1 contained only the empty vector.
3.9 Protein analysis of the DN mutant 78
M
M
M
MM
M
∆
∆
∆
∆
∆
∆
wt
wt
wt
wt
wt
wt
T1
T1
T1
T1T1
T1
T2
T2
T2
T2T2
T2
PA A
PB B
HA
38kDa
38kDa
38kDa 38kDa
49kDa 49kDa
––––
–––
–––––
–––
–––––
+
++
++
PA
A
PB
B
HA
Figure 3.20: Analysis of specific binding of sera A and B for pM94 in comparison to binding of pre-sera (PA and PB). The
infection samples mock (M), MCMV∆M94tTA (∆), and MCMV∆1-16 (wt) were analysed together with transfection samples
from pOriR6K-ie (T1) and pOriR6K-HAM94 (T2). The HA staining indicates the HA-tagged M94 in T2 at 38 kDa, whereas
serum B detected also an unspecific signal at 49 kDa. The table indicates the expected band pattern.
Both pre-sera showed minor staining, whereas the serum B demonstrated an unspecific
reaction in transfection around 49 kDa, also present in the mock control of the infection.
A band at correct size of 38 kDa was detected in the transfection of pOriR6K-HAM94, but
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not in the wt infection.
The staining with serum A resulted in a unique band at the correct size. The M94 protein
was detected by the serum A both in infection, as the signal appeared only in MCMV∆1-
16 and not in the mock or M94 deletion virus MCMV∆M94tTA infected cells, as well
as after transfection, where the empty pOriR6K-ie demonstrated no signal in contrast to
pOriR6K-HAM94. Serum A detected a single specific band at about 38 kDa corresponding
to pM94 and could be used for further experiments. This analysis also demonstrated the
antibody reaction to both, the endogenous M94 in MCMV∆1-16 and the HA-tagged M94
in pOriR6K-HAM94.
3.9.2 Analysis of the expression of M94 alleles
The inhibition demonstrated in the growth analysis should reflect the expression of the DN
mutant. Also the potential influence of the DN expression on the viral expression cascade
required investigation.
M MMwt wtwt DNDN DNDN* DN*DN*
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Figure 3.21: Analysis of the gene expression of mock control (M), MCMV∆1-16 (wt), and MCMV∆1-16svt-RM94i13 in
absence (DN) and presence (DN*) of Dox by staining with antibodies against pp89 (α-pp89), M50 (α-M50), and M94
(α-M94) at different time points (hpi). The detected proteins are indicated by arrows.
Therefore, NIH3T3 cells were infected at MOI 0.5 with mock, MCMV∆1-16, and MCMV∆1-
16svt-RM94i13 in absence and presence of Dox and protein was extracted at 8 hpi, 24 hpi,
and 36 hpi (Fig. 3.21). Following separation of the proteins by SDS-PAGE and blotting
on a membrane, the blots were stained for different proteins. The detection of pp89 by a
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specific serum served as infective control as the immediate early protein pp89 is expressed
as first viral product after infection. It is represented in figure 3.21 and its expression is
detected from 8 hpi on. The loading of gels was equilibrated on the basis of the pp89
analysis. The staining of pM50 provided a comparison to the expression of a true late
gene.
The separation of the two M94 forms was achieved by application of precasted gels from
BioRad. The M94 anti-sera detected the endogenous pM94 as well as the pHA-M94. The
staining shows the presence of the endogenous pM94 in the wt and the DN mutant in ab-
sence and presence of Dox from 24 hpi on. The HA-M94 expression is demonstrated by the
additional band present from 24 hpi on in the DN mutant in presence of Dox. The slower
migration of the HA-tagged protein is due to the additional aa in pHA-M94 resulting from
the 5 aa insertion at position i13 and the HA-tag. Altogether, the induction of the DN
mutant expression by Dox treatment and also the overexpression of the mutant compared
to the wt protein could be clearly shown.
Notably, the analysis also demonstrated the stability of the endogenous pM94 which was
not influenced by the expression of the DN mutant. The same is true for pp89 and pM50,
both were not influenced in their amount and time point of expression by expression of
the DN mutant. So the cascadic viral gene expression at least for pp89 and pM50 was not
influenced by the expression of the M94 DN mutant.
3.9.3 M94 is expressed by true late kinetics
The analysis of the M94 and the HA-M94 mutant expression at different time points did
not allow to conclude on the true late expression of either. Therefore NIH3T3 cell were
infected in absence and presence of PAA with MOI of 0.5. PAA inhibits specifically the
viral polymerase and thus viral genome replication and expression of true late genes. The
wt M94 is a true late gene, consequently dependent on the viral genome replication. As
HA-M94 was expressed under control of a different promoter it was relevant, whether its
expression kinetic was also true late.
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Figure 3.22: Gene expression analysis of several viruses in the absence (-PAA) and presence (+PAA) of PAA. NIH3T3 cell
were infected with mock control (M), MCMV∆1-16 (wt), MCMV∆1-16SVT-RHAM94 in absence (co) and presence (co*) of
Dox, and MCMV∆1-16svt-RM94i13 in absence (DN) and presence (DN*) of Dox. The blots were stained with antibodies
against pp89 (α-pp89), M50 (α-M50), and M94 (α-M94) and detected proteins are indicated by arrows.
The western blot analysis on pp89, pM50, and pM94 shown in figure 3.22 demonstrates the
mutant and wt M94 expression in absence and presence of PAA. In addition to the viruses
already analysed in Fig. 3.21, MCMV∆1-16 and MCMV∆1-16svt-RM94i13 in absence and
presence of Dox, a control virus was analysed. This overexpression control virus MCMV∆1-
16SVT-RHAM94 is equal to MCMV∆1-16svt-RM94i13, but it contains the wt HA-M94
without mutation in the conditional expression cassette.
The loading equilibration of all samples was based on the pp89 staining and as before
pM50 served as established true late gene. Accordingly, the detectable expression of M94
in all viruses disappeared by treatment with PAA. By this the true late expression of
M94 was proven. This result was expected as homologues also demonstrated true late
expression [63,95].
In contrast, the expression of pHA-M94 was not influenced by the PAA treatment indicated
by the bands present in MCMV∆1-16SVT-RHAM94 and MCMV∆1-16svt-RM94i13 both
in presence of Dox and PAA. Thus M94 expression of the inserted gene was independent
from the viral genome replication. In summary the wt M94 was expressed with true late
expression, whereas the mutant HA-M94 is not dependent on viral genome replication.
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3.10 M94 plays an essential role in secondary envel-
opment
In order to localise the inhibition in the lytic cycle by the expression of the DN mutant,
transmission electron microscopy (EM) was performed. In parallel the ultra structural
phenotype of the M94 deletion virus was also studied for comparison.
To this end, NIH3T3 cells were infected with a MOI of 1 and centrifugal enhancement
for one hour with MCMV∆1-16, MCMV∆M94tTA and MCMV∆1-16svt-RM94i13 in ab-
sence and presence of Dox. Afterwards cells were fixed by high-pressure freezing, freeze-
substituted, plastic embedded, thin-sectioned and analysed by transmission electron mi-
croscopy [93]. Both viruses under all conditions showed a wt-like capsid distribution in the
nucleus (Fig. 3.23) and also primary envelopment mainly on nuclear infoldings (Fig. 3.24).
Next, the analysis demonstrated secondary envelopment namely tegumented enveloped
capsids in the cytoplasm for the wt virus as well as the DN virus in absence of Dox indi-
cated by arrows. In contrast no secondary envelopment could be detected in cells infected
with the M94 deletion mutant or the M94 DN expressing virus in presence of Dox although
tegumented capsid accumulations in the centre of an assembly complex-like structure were
present, indicating a role of M94 in the secondary envelopment. In addition enveloped
viral particles were also not observed in vesicles, which are believed to appear ahead of the
secondary envelopment.
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Figure 3.23: Electron microscopy analysis of cells infected by MCMV∆1-16 (wt), MCMV∆M94tTA (∆) and MCMV∆1-
16svt-RM94i13 in absence (DN) and presence (DN*) of Dox. A representative view of the cell including nucleus (N) and
cytoplasm (C) is shown.
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Figure 3.24: Electron microscopy analysis of the primary envelopment of MCMV∆1-16 (wt), MCMV∆M94tTA (∆) and
MCMV∆1-16svt-RM94i13 in absence (DN) and presence (DN*) of Dox in the nucleus is presented.
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Figure 3.25: Electron microscopy analysis illustrating the secondary envelopment of MCMV∆1-16 (wt), MCMV∆M94tTA
(∆) and MCMV∆1-16svt-RM94i13 in absence (DN) and presence (DN*) of Dox in the cytoplasm. Secondary envelopment
is indicated by arrows.
3.11 Spread deficiency of MCMV lacking M94
Until now it is unclear whether secondary envelopment is required for cell-to-cell spread
in β-Herpesvirinae [82]. The lack of secondary envelopment in presence of functional M94
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raised the question whether this also results in a loss of cell-to-cell spread. In order to
analyse the spread phenotype of the M94 deletion virus, NIH3T3 and NTM94 cells were
infected with wt and M94 deletion virus. The remaining virus was removed by intensive
washing and CFSE stained NIH3T3 were added. Virus spread was then permitted for
48 h. Afterwards, the culture was stained against immediate early antigen pp89, resulting
in cells either pp89-positive, CFSE-positive, double positive or double negative for both
stains [48].
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Figure 3.26: Analysis of the spread assay. A schematic diagram of the spread assay is shown in A, whereas B illustrates
representative pictures of pp89 (red) and CFSE (green) stained NIH3T3 (3T3) and NTM94 (NTM94) cells infected by
either MCMV∆1-16 (wt) or MCMV∆M94tTA (∆). Virus transmission was determined by calculating the ration between
pp89-positive/CFSE stained cells to pp89-negative/CFSE stained cells (C).
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Cells positive for both stains indicate the transmission of virus from infected CFSE neg-
ative cells to CFSE positive cells. Figure 3.26 shows a scheme of the spread assay and
images by confocal microscopy. Virus transmission was determined by counting pp89-
and CFSE-positive cells resulting in the depicted transmission rate by determination of
the ratio between pp89-positive/CFSE stained cells to pp89-negative/CFSE stained cells.
Thereby the ability of the wt virus to spread rapidly throughout the cell population was
demonstrated by a transmission rate of 100 %. In contrast the M94 deletion virus was
unable to infect the freshly added cells. This lack of cell-to-cell spread was restored by
using the complementing cell line NTM94 in the assay resulting in a transmission rate
of 97 %. This analysis demonstrated that the deletion of M94 resulted in a block of the
induction of both release of infectious particles and cell-to-cell spread.
3.12 M94 is not essential for viral cleavage-packaging
Since Nalwanga et al. [63] localised pUL16, the homologue of pM94 in intranuclear as-
semblons and Oshima et al. [64] discovered the single strand (ss) DNA binding of pUL16
the HSV homolog of pM94, there are speculations on the involvement of M94 and its
homologues in cleavage-packaging of viral genomes [45]. Our EM analysis indicated no
detectable defect in the nuclear morphogenesis in absence of functional M94. Yet an ac-
cessory role of M94 in packaging could not be excluded by the EM analysis. In order
to investigate cleavage-packaging, an assay for the end cleavage reaction in MCMV infec-
tion was designed. By Southern blot analysis the different genome forms present in the
cleavage-packaging process could be separated.
As already mentioned in the introduction, the genomes of Herpesviridae are replicated as
head-to-tail concatemers.
The concatemers depicted in figure 3.27(A) are cleaved into unit-length genomes by the
terminase enzyme of the virus and inserted into preformed capsids (B). This process is
highly conserved throughout the Herpesviridae. The events of genome cleavage and pack-
3.12 M94 is not essential for viral cleavage-packaging 88
a
a a
a
a aa
b b b
b b b
b
A
B
Figure 3.27: Schematic diagram of head-to-tail concatemers (A). Several MCMV genomes with terminal repeats a and b are
illustrated as boxes in the head-to-tail-concatemeric form. The concatemer is cleaved by the terminase (black arrowhead)
and the unit length genome is packed into the capsid (B).
aging are coupled and therefore appear simultaneously.
The viral genome replication proceeds by production of concatemers. The capsid assem-
bles simultaneously into procapsids, in which the unit length genomes are inserted from
the head-to-tail concatemers. Therefore, during encapsidation the concatemers need to be
cleaved into unit length genomes by the viral terminase. Through this parallel process
concatemers and unit-length genomes coexist during late stage of viral replication. To
distinguish between these two forms, a digestion of viral DNA and a fragment detection
by Southern blot analysis were combined.
3.12.1 Packaging assay
To analyse the viral DNA with regard to DNA cleavage-packaging, the total DNA from
infected cells harvested at 48 hpi was isolated, digested by ApaLI, and subjected to by
agarose gel electrophoresis. The two genome forms were separated by their fragment size
indicated by a probe in a Southern blot analysis.
A similar assay was already established in the group by Mirela Popa [68], but this assay was
not suitable for analysis of constructs based on pSM3fr-FRT-∆1-16 and therefore a new
assay based on the same principle was established in this study to analysis pSM3fr-FRT
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and pSM3fr-FRT-∆1-16 based constructs in parallel.
For the detection of both genome forms, a probe detecting two ApaLI-fragments was
generated. Figure 3.28 illustrates the products derived from concatemers and cleaved
genomes.
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7 kbp
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9 kbp
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Figure 3.28: Position of the Southern probe on the concatemeric genome form (A) and cleaved genomes (B). The ApaLI
restriction sites are displayed in blue and the green lines represent the genome termini, whereas the FRT site is indicated by
a red arrow. Fragments detected by the probe are indicated with their corresponding sizes.
Two fragments were detected by the probe, irrespective whether the genome was cleaved
or in its concatemeric form (Fig. 3.28). The control fragment of 7 kbp representing an
internal genomic fragment was utilised for normalisation of loading of the samples. The
terminal fragment representing unit-length genomes was produced by the ApaLI digest at
the hybridisation position of the probe and the cleavage into unit-length genomes at the
genome termini by the viral terminase, resulting in a 5.5 kbp fragment. The size of the
fragment identifying the concatemers varied. These terminal fragments resulted from the
ApaLI digest beyond the genome termini and had a size of 6.5 kbp in wt, 6.7 kbp in the
pSM3fr-FRT-∆1-16 backbone and 9 kbp in the pSM3fr-FRT backbone. In pSM3fr-FRT-
∆1-16 the ectopic insertion at the FRT site relocates the ApaLI restriction site generating
a larger fragment than in the wt. In pSM3fr-∆M94tTA the non deleted genes m01 to m16
prolonged the fragment.
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Figure 3.29: Packaging assay for mock (M), MCMV∆M94tTA (∆), MCMV∆1-16 (wt), MCMV∆1-16svt-RM94i13 in absence
(DN) and presence (DN*) of Dox, and MCMV∆1-16-EHAM94 (oc) at MOI 0.5 and 0.1 for two independent analyses (A and
B) at different exposure times (min). The BACs pSM3fr-FRT-∆1-16 (B1), pSM3fr-∆1-16svt-RM94i13 (B2), and pSM3fr-
∆1-16-EHAM94 (B3) were analysed as concatemeric controls. The fragments representing the control 7 kbp, the cleaved
genomes 5.5 kbp and all concatemeric fragments 9 kbp, 6.7 kbp and 6.5 kbp, are indicated.
Figure 3.29 shows the result of the packaging assay. DNA from infections with mock,
M94 deletion MCMV∆M94tTA, wt MCMV∆1-16, DN mutant MCMV∆1-16svt-RM94i13
in absence and presence of Dox and control virus MCMV∆1-16-EHAM94 which consti-
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tutively expresses HA-M94 were analysed. Next to the infection samples the BACs for
generation of the viruses were analysed. Due to the circular form of the BACs no free
terminal fragments were present resulting in two bands, one for the concatemeric form and
the control band.
The control fragment of 7 kbp was present in all samples, but varied in intensity due to
different loading. The equilibration based on the 7 kbp fragment was required due to
different amounts of viral DNA in the DNA extractions but as almost no viral DNA was
produced in the spread deficient MCMV∆M94tTA the complete extraction was utilised in
one analysis. Therefore equilibration was complicated and loading differed in both analysis
A and B and reduced the comparability.
The upshift of the 6.5 kbp concatemeric fragment of MCMV∆1-16 to the 6.7 kbp concate-
meric fragment of MCMV∆1-16svt-RM94i13 and MCMV∆1-16-EHAM94 is reflected by
the analysis as well as the 9 kbp concatemeric fragment of MCMV∆M94tTA. The 5.5 kbp
fragment representing the cleaved genomes was present in all samples, while the band of
∆ in analysis B was shifted due to the excessive loading.
Due to divers loading a direct comparison of ration of fragments was not feasible and only
the appearance of all fragments for all mutants was detected.
In order to equilibrate the differences caused by the differences in the amount of genome
loads, the band intensities were compared. Therefore the chemiluminescence signal was as-
sessed using a chemiluminescence scanner and quantified by computer analysis (Tab. 3.30).
Table 3.3: Values of the quantification of the packaging assay corresponding to figure 3.30
∆ wt DN DN* oc
control 23,217 7392 6012 6651 135,178
concatemer 8831 4008 3257 3328 67,590
cleaved 16,280 5848 4483 5306 101,521
By plotting the relative intensities of the three bands of one sample, the ratio between
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Figure 3.30: Quantification of the packaging assay. The chemiluminescence signals of the Southern analysis (Fig. 3.29)
were detected and quantified. Values for each genome form of MCMV∆M94tTA (∆), MCMV∆1-16 (wt), MCMV∆1-16svt-
RM94i13 in absence (DN) and presence (DN*) of Dox, and MCMV∆1-16-EHAM94 (oc) were compared to each other. The
relative intensities of the control fragment (black), concatemeric fragment (green) and cleaved fragment (blue) are illustrated
in percentage.
the fragments was determined (Fig. 3.30). Analyses of both assays were used, except
MCMV∆M94tTA, and mean values are depicted. The control fragment is illustrated in
black and constitutes approximately 50 % of the total fragments as it was present both
in the concatemers and the cleaved genomes. The percentage of the concatemeric form
(green) was lower than the percentage of the cleaved genomes (blue), representing the
proportion seen in the assay (Fig. 3.29).
Altogether, the analysis demonstrated a stable ratio between concatemeric and unit-length
genomes for all tested viruses. Neither the deletion of M94 nor the expression of the DN
mutant resulted in any influence on the ratio between concatemeric and cleaved genome
form. The phenotype of both mutants was comparable to wild type. This demonstrates
that M94 plays no essential role in the cleavage-packaging process of viral genomes.
Chapter 4
Discussion
The aim of this project was to investigate the essential function of the MCMV protein
M94. By analysis of a library of M94 mutants generated by a Tn7 based mutagenesis
in the viral context, sequences affecting essential protein functions were identified. These
loss-of-function mutants were used to identify DN mutants of M94. These DN mutants
were analysed in comparison to the M94 deletion mutant. This study revealed that M94
plays an essential role in secondary envelopment and also that M94 deletion is sufficient for
loss of cell-to-cell spread. In addition, it could be demonstrated that M94 is not required
for cleavage-packaging of the viral genome.
4.1 Generation of mutant libraries
The established transposon mutagenesis and subsequent analysis in the viral context per-
mits the definition of essential genes. This is especially useful for genes with unclear
function like M94 as by this analysis regions in the protein essential for virus replication
can be located and also potential DN mutants can be identified. By further characterisa-
tion of the mutants, the step of the essential contribution of the protein function in the
virus life cycle can be determined.
Our previous mutagenesis procedure used for the analysis of the protein M53 could be sig-
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nificantly improved during this study. Former transposon mutageneses suffered from the
presence of numerous clones including mutations in the backbone of the mutated plasmid
in addition to the desired mutations in the gene of interest. These vector mutations needed
to be separated from the mutations in the gene of interest. This problem was solved during
M53 mutagenesis [47] by subcloning M53 including the transprimer from the target vector
into an expression vector. This procedure was also performed in this study. Despite this
advancement, the mutagenesis of M53 experienced several throwbacks.
First of all, the utilised donor vector in the M53 mutagenesis was constructed from pGPS4
and pST76K [46] and contained a temperature sensitive origin of replication. So that
the donor vector was in subsequent steps rejected from the mutagenesis at non-permissive
temperature. In contrast, pGPS4 included in the GPS R©-LS Linker scanning system from
NEB was utilised in the M94 mutagenesis. Therefore the necessity of a special donor vec-
tor which is commercially not available was omitted. This makes the procedure generally
applicable.
Secondly, the first analysis of the final M53 library revealed the necessity of preselection
of mutants by PCR as about 50 % of the mutants did not contain M53 for unknown rea-
sons or were truncation mutants. Among 986 M53 mutants analysed by PCR only 498
were selected for sequencing. Thereby the labour intensive mutant analysis was increased
by an additional procedure. This preselection was eliminated in the M94 mutagenesis as
the first analysis of the final library demonstrated no mutations outside of the subcloned
fragment (Fig. 3.9). Therefore M94 mutants from the library could be directly forwarded
to sequencing.
Table 4.1: Comparison of the transposon mutagenesis of M53 and M94.
M53 mutagenesis M94 mutagenesis
sequenced mutants 498 613
correct mutants 389 494
unique mutants 109 399
The quantity of sequenced, correct and unique mutants for the M53 library and the M94
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library are presented in table 4.1. Subsequently to preselection, 498 mutants of the M53
library have been sequenced, whereas 613 mutants of the M94 library were sequenced. In
the M53 library 389 of the sequenced mutants contained a single correct mutation in the
M53-ORF. This is a comparable proportion of 80 % of mutants as in the M94 library
where 494 of the 613 sequenced mutants were correct. In the M94 library half of the
incorrect mutants resulted from using GPS R©-LS Linker scanning system as mentioned
in the manual [7]. The remaining 10 % incorrect mutations contained 5 % mixed clones.
Mutations outside the M94-ORF due to imprecise subcloning constituted the remaining 5 %
of incorrect mutations. Analogue reasons caused incorrect mutations in the M53 library.
The libraries are then comparable in this point, disregarding the omitted preselection of
the M94 library.
However, there is a definitive enhancement of resolution in the M94 library compared to
the M53 library. The M94 library contained 80 % (399 of 494) unique mutants, whereas the
M53 library included only 28 % (109 of 389) unique mutants. Certainly a direct comparison
is complicated as diverse methods were applied on different genes. However, we believe
that the cloning bias seen in the M53 mutagenesis was eliminated in the M94 mutagenesis.
This resulted in an enhanced assortment of mutants for a detailed analysis of M94.
A B
Figure 4.1: Comparison of the coverage of insertion mutants of the M53 library [46] (A) and the M94 library (B) generated
in this study.
Due to the increased unique number of mutants in the M94 library, the coverage could also
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be enhanced. This is demonstrated by the maximal interval of 20 aa between two insertion
mutation in the M53 library and of 12 aa in the M94 library as depicted in figure 4.1 and
also by the average distance of two insertion mutations of 7.2 aa (46 insertions mutations
in 333 aa) in the M53 library and of 5.75 aa (60 insertion mutation in 345 aa) in the M94
library.
4.2 Analysis of M94 mutants by cis-complementation
The growth properties of the M94 deletion virus demonstrated first, that M94 is essential
and second, that the null phenotype can be restored by cis-complementation at an ectopic
potition in the genome under control of a foreign promoter. This result was a necessary
prerequisite for the systemic analysis of M94 mutants in the viral context. The read out
of successful viral reconstitution from transfected BACs or failure served as a relevant but
simple assay. This was important as the essential function of M94 was unknown, therefore
the generated mutants could not be analysed for a specific function. Instead, any essential
function of M94 in the viral life cycle was detected and located to a specific site in the M94
protein by the individual analysis of the M94 mutants.
The analysis of 14 truncation mutants revealed that only the last three aa of the C-
terminus of M94 are dispensable for its essential function(s). As in the UL16/94 family
the C-terminus was already described to be conserved [95] and also essential for binding of
UL16 to UL11 [96], this result is consistent with the literature. Also the in silico analysis
predicted an α-helix in the C-terminus, which overlapped with the four insertion mutants,
that did not complement wt M94. Therefore this C-terminal α-helix seems to be important
for the essential function of M94.
Out of the 60 tested insertion mutants 39 kept the function of M94, whereas the remaining
21 failed to complement wt M94. These non-complementing mutations are for the most
part arranged in clusters in the N-terminus, the C-terminus, and between aa 234 and 244
indicating a functional site in this region. However, in the bioinformatically predicted
linker region (aa 121-170) only a single insertion mutant out of 7 demonstrated a non-
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complementing phenotype hence supporting the prediction. The same is probably true for
the region of aa 254 to 299 even though a linker region is not predicted. Therefore the
bioinformatic analysis could only partially be confirmed.
4.3 Identification and analysis of DN mutants
The identification of a DN mutant can be a difficult task, in particular, if knowledge about
the protein structure is limited and therefore a targeted mutation is impossible. Hence, a
random approach for identification as utilised in this study remains the only chance.
Subsequently to the analysis of the M94 mutants in the cis-complementation assay, the
lethal mutants demonstrating no viral reconstitution in this assay and some additional
stop mutants in the C-terminus were subjected to the inhibitory screen. In total 42 lethal
mutants were analysed for their ability to inhibit viral reconstitution in presence of the M94
wt allele. The lethal phenotype in the cis-complementation assay can be due to different
reasons such as incorrect folding, protein instability or aberrant localisation of the protein.
The mutants identified by the inhibitory screen need to keep a wt function, namely the
ability to form complexes and lose other distinct functions.
Only 2 inhibitory mutants were found. Surprisingly they were located in the N-terminus
of the protein. As the C-terminus is conserved and found to carry an essential site, the
inhibitory mutants were expected to be located in this region, especially as the N-terminus
was not correlated with any functionality or conservation until then.
In order to verify the inhibitory phenotype of the mutants and exclude toxic effects they
were subcloned into an inducible expression cassette. The growth analysis demonstrated
the actual inhibition of viral growth due to Dox treatment by 3 orders of magnitude.
The following analysis of the protein expression demonstrated that the HA-tagged M94
mutant was indeed expressed upon Dox treatment. Also, the overexpression of M94i13
compared to M94 was demonstrated. As the inhibition in presence of the wt allele was
related to the overexpression of the mutant in presence of Dox, this mutant was identified
as a DN mutant as defined previously [36].
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The analysis revealed that the stability of the wt protein was not affected by the expression
of the DN mutant as the expression levels were comparable regardless of the DN expression.
The analysis of the expression of a representative IE gene pp89 and a representative late
gene pM50 at different time points showed no effect on the viral gene expression due to the
expression of M94i13. The data indicated that viral gene expression was not influenced by
the expression of the DN mutant. The analysis of M94 expression in the presence of PAA
hence inhibiting the viral DNA replication showed that endogenous M94 was expressed
with true late kinetics. Due to the SV40 promoter driving the M94i13 expression, this
protein was not expressed with true late kinetics.
4.4 Comparative analysis of the M94 deletion and DN
mutant
To identify the function in the MCMV life cycle which is inhibited by the DN mutant
transmission electron microscopy was performed. A complementing cell line for the M94
deletion virus was available and it was analysed along with the DN mutant. Previous
publications predicted a role for M94 in viral cleavage-packaging [63, 64]. If this would be
an essential function of M94 the primary envelopment, namely the envelopment of filled
capsids at the inner nuclear membrane (INM) and de-envelopment at the outer nuclear
membrane (ONM), should be affected or at least more unfilled capsids should be visible
in the nucleus. Surprisingly, the primary envelopment seemed not to be affected in both
mutants and the phenotype of the M94 deletion mutant and the M94 DN mutant was
comparable to wt.
The EM demonstrated a loss of secondary envelopment as the reason for the inhibition of
viral growth. Even more, there were no viral particles in vesicles present at all, although
tegumented capsids were present in the cytoplasm. This phenotype of tegumented filled
capsids accumulating in the cytoplasm next to the Golgi compartment demonstrates an
accurate process of the virus life cycle up to this point but the incapability to proceed by
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acquiring the final envelope.
Next to its role in viral cleavage-packaging, a role in secondary envelopment has also been
proposed for UL16 in HSV due to its interaction with UL11 [96]. Therefore, the loss of
secondary envelopment was in line with this prediction. The two genetically different and
independent constructs either deletion or DN mutant protein demonstrated the identical
phenotype with respect to secondary envelopment and therefore excluded artifacts in the
genetic procedure or in the EM analysis.
Previous study on deletion mutants, namely the UL99 deletion virus of HCMV, demon-
strated a comparable loss of secondary envelopment [82]. Despite this finding, the study
revealed that the virus was still able to spread from cell to cell. Therefore the same was
investigated for the M94 deletion virus in a spread assay.
The results demonstrated, in contrast to the UL99 deletion virus, a spread deficient pheno-
type. The deficient phenotype was reverted to almost wt by applying the complementing
cell line providing pM94 in the assay. Thus the loss of cell-to-cell spread was solely due
to the lack of M94. From this result we concluded that the exclusive deletion of M94 is
sufficient for a total block in cell-to-cell spread.
As mentioned earlier, primary envelopment of MCMV was not affected by deletion of M94
or by expression of the M94 DN mutant. As previous publications discussed a role of M94
homologues in viral cleavage-packaging due to localisation in assemblons [63] and ssDNA
binding [64] this potential role was investigated in more detail by a newly designed pack-
aging assay. This analysis clearly demonstrated that cleavage of viral genomes was present
in comparable quantities for wt, the DN mutant and the deletion mutant. As cleavage
and packaging are connected and appear simultaneously, we concluded that M94 has no
essential function in viral cleavage-packaging and confirmed by the packaging assay the
observations of the electron microscopy. This data also demonstrated that at least for
β-Herpesvirinae the primary and secondary envelopment are mechanistically separated.
4.5 M94 is a key player in secondary envelopment of β-Herpesvirinae 100
4.5 M94 is a key player in secondary envelopment of
β-Herpesvirinae
The complex life cycle of the different Herpesvirinae subfamilies involves formation of cap-
sids in the nucleus, the encapsidation of the viral genome, transfer of the filled capsid into
the cytoplasm, tegumentation, final envelopment and egress of viral particles. Although
differences in the subfamilies exist, especially the processes in the nucleus are conserved
and share significant homologies. The capsid assembles out of 5 capsid proteins into the
procapsid. After a protease maturation step the viral genome is inserted into the capsid
via the capsid portal by the viral terminase, a complex comprised of 3 conserved proteins.
The concatemers derived from the rolling cycle replication of the viral genome are cleaved
into unit-length genomes by the viral terminase and simultaneously encapsidated. The fol-
lowing pathway of transfer of the filled capsids into the cytoplasm is still under discussion.
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Figure 4.2: Schematic representation of models of nuclear egress of herpesvirus particles. The dual envelopment hypothesis
(A) includes acquisition of a primary envelope at the INM after budding into the perinuclear space and subsequently loss of
this primary envelope by fusion with the ONM. The resulting cytosolic capsids undergo a secondary envelopment at the TGN,
from where they are transported in vesicles to the plasma membrane. In the single envelopment hypothesis (B) the capsid
also buds into the perinuclear space acquiring its envelope and subsequently enters a transport vesicle at the ONM which
directly delivers the virions to the plasma membrane. The third model (C) is characterised by egress of the nucleocapsid
through an enlarged nuclear pore (np) and the only envelopment occurs at endoplasmic reticulum (ER) or Golgi followed by
budding into vesicles for transport.
Three models for the nuclear egress are currently discussed (Fig. 4.2). Two of these include
only a single envelopment of capsid either at the ONM or at the ER/Golgi compartment.
The remaining model assumes two spatially and temporarily separated envelopment pro-
4.5 M94 is a key player in secondary envelopment of β-Herpesvirinae 102
cesses, the primary envelopment at the INM and the secondary envelopment at the TGN.
Studies in α-Herpesvirinae of different deletion mutants demonstrated blocks in primary
and secondary envelopment. However, for a complete block in secondary envelopment in
α-Herpesvirinae multiple gene deletions are required, a single deletion mutant exhibiting
this phenotype was not identified so far. In this study a single deletion mutant causing a
loss of secondary envelopment was identified. This proves that the primary and secondary
envelopment are distinct processes as primary envelopment is not inhibited in the M94
deletion virus and the M94 DN virus. In contrast to the uninfluenced primary envelop-
ment the secondary envelopment is lost for both mutants. The first process then proceeds
like wt, whereas the second process is inhibited demonstrating the autonomy of the two
processes from each other.
The identification of a M94 DN mutant leads to the conclusion of at least two essential
functions inherited by M94 as one function probably binding in a complex needs to remain
like wt, whereas a second function must be destroyed to generate the inhibitory pheno-
type. One of these functions is located in the N-terminus of M94 as mutations in this
region specifically inhibited a protein function causing the DN phenotype. The second
essential function might well be located in the C-terminus of M94 as this was identified
as an essential region in the loss-of-function screen. Although other reasons as incorrect
protein folding might have resulted in the lethal phenotype of the C-terminal mutants, the
assumption of an essential region related to a distinct protein function is reasonable. A
publication on the α-Herpesvirinae homologue UL16 demonstrated a transient binding of
UL16 to the viral capsid by the conserved cysteines of UL16 family members, which are
located in the C-terminus of the homologues [53]. The strict conservation of these cysteines
implies a function related to these cysteines, which is also conserved and shared between
α-Herpesvirinae and β-Herpesvirinae. So from the two essential functions of M94 one is
located in the N-terminus and the second one probably in the C-terminus.
Another known function of UL16 family members is the interaction with UL11 family
members, which was shown in HSV [45] and HCMV [43]. UL11 and its HCMV homologue
UL99 are small myristylated proteins which associate with membranes via a membrane
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anchor and are known to be involved in secondary envelopment [4, 83]. This binding is
most likely present in MCMV not only due to the high homology of HCMV and MCMV
but also as it links M94 to secondary envelopment. Preliminary studies in our lab to iden-
tify viral binding partners of M94 confirmed the binding to the UL11 family member of
MCMV M99. This interaction was lost in the analysis of the M94 DN mutant (unpublished
data). We therefore speculate that the binding site for the M99 interaction is located in
the N-terminus of M94.
This hypothesis leads to a model for secondary envelopment involving M99, M94, and the
nucleocapsid. In this model M94 binds to the capsid and by interaction with M99 connects
the capsid to the TGN, where M99 acts as membrane anchor as shown in figure 4.3.
TGN membrane
M99
M94
nucleocapsid
Figure 4.3: Model for secondary envelopment involving the nucleocapsid, M94 and M99 including its membrane anchor at
the TGN membrane.
It is known that secondary envelopment in α-Herpesvirinae involves more proteins than in
β-Herpesvirinae, for example several glycoproteins. This redundancy is also demonstrated
by the dispensability of UL16 in HSV. The model for secondary envelopment presented
here reveals the key function of M94 in β-Herpesvirinae. It is the unique protein connect-
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ing the capsid to the TGN membrane. Therefore the deletion of M94 or inhibition of this
bridging function results in a complete loss of secondary envelopment.
Further experiments are required to strengthen the model presented here. First, the M94-
M99 interaction needs to be verified in MCMV by pull-down experiments and immunoflu-
orescense. Subsequently the M99 binding site in M94 can be mapped by fragment com-
plementation assay using the mutants generated in this study. In addition, isolation of
capsids and identification of bound M94 will reveal the validity of this model.
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